業績

研究業績

• 原著論文
• 症例報告

2021年|  2020年 | 2019年 | 2018年 | 2017年 | 2016年 | 2015年 | 2014年 | 2013年 | 2012年 | 2011年 | 2010年 | 2009年 | 2008年 | 2007年 | 2006年 | 2005年

原著論文

2023年

1. Zhang S, Tsuji H, Jin H, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Tanaka M, Arase H, Ohmura K, Morinobu A. Rheumatoid Factor Recognizes Specific Domains of the IgG Heavy Chain Complexed with HLA Class II Molecules. Rheumatology (Oxford). 2023 Jan 16:kead024. doi: 10.1093/rheumatology/kead024. Epub ahead of print. PMID: 36645239.
2. Nakajima T, Doi H, Watanabe R, Murata K, Takase Y, Inaba R, Itaya T, Iwasaki T, Shirakashi M, Tsuji H, Kitagori K, Akizuki S, Nakashima R, Onishi A, Yoshifuji H, Tanaka M, Ito H, Hashimoto M, Ohmura K, Morinobu A. Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus Cohort. Mod Rheumatol. 2023 Jan 21:road014. doi: 10.1093/mr/road014. Epub ahead of print. PMID: 36680424.
3. Watanabe R, Murakami K, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Morinobu A, Hashimoto M. Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort. Immunol Med. 2023 Jan 23:1-9. doi: 10.1080/25785826.2023.2170384. Epub ahead of print. PMID: 36688476.
4. Gon Y, Kandou T, Tsuruyama T, Iwasaki T, Kitagori K, Murakami K, Nakashima R, Akizuki S, Morinobu A, Hikida M, Mimori T, Yoshifuji H. Increased number of T cells and exacerbated inflammatory pathophysiology in a human IgG4 knock-in MRL/lpr mouse model. PLoS One. 2023 Feb 10;18(2):e0279389. doi: 10.1371/journal.pone.0279389. PMID: 36763580; PMCID: PMC9916631.
5. Nishimura N, Niwamoto T, Arai Y, Nakashima R, Terada K, Yoshizawa A, Sakamoto R, Tanizawa K, Handa T, Morinobu A, Hirai T. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders in a patient with anti-melanoma differentiation-associated gene 5-positive dermatomyositis: A case report and systematic literature review. Int J Rheum Dis. 2023 Feb 15. doi: 10.1111/1756-185X.14608. Epub ahead of print. PMID: 36789793.
6. Umemoto A, Kuwada T, Murata K, Shiokawa M, Ota S, Murotani Y, Itamoto A, Nishitani K, Yoshitomi H, Fujii T, Onishi A, Onizawa H, Murakami K, Tanaka M, Ito H, Seno H, Morinobu A, Matsuda S. Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2023 Feb 17;25(1):25. doi: 10.1186/s13075-023-03007-9. PMID: 36804906; PMCID: PMC9936655.
7. Onishi A, Tsuji H, Takase Y, Nakakubo Y, Iwasaki T, Kozuki T, Yoshida T, Shirakashi M, Onizawa H, Hiwa R, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Tanaka M, Morinobu A. Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes. Rheumatology (Oxford). 2023 Mar 21:kead132. doi: 10.1093/rheumatology/kead132. Epub ahead of print. PMID: 36943365.
8. Watanabe R, Kadoba K, Tamamoto A, Murata K, Murakami K, Onizawa H, Fujii T, Onishi A, Tanaka M, Ito H, Morinobu A, Hashimoto M. CD8⁺ Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis. J Clin Med. 2023 Mar 17;12(6):2342. doi: 10.3390/jcm12062342. PMID: 36983342; PMCID: PMC10054757.
9. Yamaguchi E, Kadoba K, Watanabe R, Hashimoto M, Morinobu A, Yoshifuji H. Response to: ‘Biases in Large Vessel Vasculitis’ by Mukhtyar. Mod Rheumatol. 2023 Apr 1:road035. doi: 10.1093/mr/road035. Epub ahead of print. PMID: 37027011.
10. Onishi A, Torii M, Hidaka Y, Uozumi R, Oshima Y, Tanaka H, Onizawa H, Fujii T, Murata K, Murakami K, Tanaka M, Matsuda S, Morinobu A, Arai H, Hashimoto M. Efficacy of personalized exercise program on physical function in elderly patients with rheumatoid arthritis at high risk for sarcopenia: study protocol for a randomized controlled trial. BMC Musculoskelet Disord. 2023 Apr 11;24(1):280. doi: 10.1186/s12891-023-06185-4. PMID: 37041556; PMCID: PMC10088120.
11. Nakamachi Y, Uto K, Hayashi S, Okano T, Morinobu A, Kuroda R, Kawano S, Saegusa J. Exosomes derived from synovial fibroblasts from patients with rheumatoid arthritis promote macrophage migration that can be suppressed by miR-124-3p. Heliyon. 2023 Mar 30;9(4):e14986. doi: 10.1016/j.heliyon.2023.e14986. PMID: 37151687; PMCID: PMC10161379.
12. Kitagori K, Oku T, Wakabayashi M, Nakajima T, Nakashima R, Murakami K, Hirayama Y, Ishihama Y, Ohmura K, Morinobu A, Mimori T, Yoshifuji H. Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2023 May 10;25(1):76. doi: 10.1186/s13075-023-03057-z. PMID: 37165399; PMCID: PMC10170829.
13. Nishida Y, Shirakashi M, Hashii N, Nakashima R, Nakayama Y, Katsushima M, Watanabe R, Onizawa H, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Onishi A, Murakami K, Yoshifuji H, Tanaka M, Tsuruyama T, Morinobu A, Hashimoto M. Pathogenicity of IgG-Fc desialylation and its association with Th17 cells in an animal model of systemic lupus erythematosus. Mod Rheumatol. 2023 Jun 10:road054. doi: 10.1093/mr/road054. Epub ahead of print. PMID: 37300805.
14. Nakayama Y, Nakashima R, Handa T, Ohsumi A, Yamada Y, Nakajima D, Yutaka Y, Tanaka S, Hamada S, Ikezoe K, Tanizawa K, Shirakashi M, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Yoshifuji H, Date H, Morinobu A. Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study. Sci Rep. 2023 Jun 22;13(1):10150. doi: 10.1038/s41598-023-37141-w. PMID: 37349495; PMCID: PMC10287698.
15. Nakayama Y, Watanabe R, Yamamoto W, Ebina K, Hirano T, Kotani T, Shiba H, Katayama M, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Murakami K, Murata K, Ito H, Tanaka M, Matsuda S, Morinobu A, Hashimoto M. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford). 2023 Jun 24:kead299. doi: 10.1093/rheumatology/kead299. Epub ahead of print. PMID: 37354495.
16. Nakajima S, Tsuchiya H, Ota M, Ogawa M, Yamada S, Yoshida R, Maeda J, Shirai H, Kasai T, Hirose J, Ninagawa K, Fujieda Y, Iwasaki T, Aizaki Y, Kajiyama H, Matsushita M, Kawakami E, Tamura N, Mimura T, Ohmura K, Morinobu A, Atsumi T, Tanaka Y, Takeuchi T, Tanaka S, Okamura T, Fujio K. Synovial Tissue Heterogeneity in Japanese Patients With Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach. Arthritis Rheumatol. 2023 Dec;75(12):2130-2136. doi: 10.1002/art.42642. Epub 2023 Nov 5. PMID: 37390361.
17. Naito R, Ohmura K, Higuchi S, Nakai W, Kohyama M, Mimori T, Morinobu A, Arase H. Positive and negative regulation of the Fcγ receptor-stimulating activity of RNA-containing immune complexes by RNase. JCI Insight. 2023 Aug 22;8(16):e167799. doi: 10.1172/jci.insight.167799. PMID: 37432743; PMCID: PMC10543717.
18. Masui S, Yonezawa A, Nakamura M, Onishi A, Hashimoto M, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Yokoyama K, Iwamoto N, Shimada T, Itohara K, Hira D, Nakagawa S, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K. Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis. Biol Pharm Bull. 2023;46(8):1112-1119. doi: 10.1248/bpb.b23-00192. PMID: 37532562.
19. Shirata M, Ito I, Tanaka M, Murata K, Murakami K, Ikeda H, Oi I, Hamao N, Nishioka K, Hayashi Y, Nagao M, Hashimoto M, Ito H, Ueno H, Morinobu A, Hirai T. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Clin Exp Med. 2023 Dec;23(8):4707-4720. doi: 10.1007/s10238-023-01163-5. Epub 2023 Aug 16. PMID: 37582911.
20. Umemoto A, Ito H, Azukizawa M, Murata K, Tanaka M, Fujii T, Onishi A, Onizawa H, Ishie S, Murakami A, Nishitani K, Murakami K, Yoshitomi H, Hashimoto M, Morinobu A, Matsuda S. How do symptoms of each joint contribute to global pain, disease activity and functional disability in rheumatoid arthritis?-A comprehensive association study using a large cohort. PLoS One. 2023 Aug 25;18(8):e0285227. doi: 10.1371/journal.pone.0285227. PMID: 37624815; PMCID: PMC10456163.
21. Sasai T, Nakashima R, Tsuji H, Nakajima T, Imura Y, Yoshida Y, Hirata S, Shirakashi M, Hiwa R, Kitagori K, Akizuki S, Yoshifuji H, Mimori T, Morinobu A. Long-Term Prognosis of Antimelanoma Differentiation-Associated Gene 5-Positive Dermatomyositis With Interstitial Lung Disease. J Rheumatol. 2023 Nov;50(11):1454-1461. doi: 10.3899/jrheum.2023-0371. Epub 2023 Sep 15. PMID: 37714541.
22. Taniguchi T, Hiwa R, Morinobu A. The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody-associated vasculitis is premature. Kidney Int. 2023 Oct;104(4):856. doi: 10.1016/j.kint.2023.07.008. PMID: 37739617.
23. Mukoyama H, Murakami K, Onizawa H, Shirakashi M, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Nakashima R, Onishi A, Yoshifuji H, Tanaka M, Morinobu A. A case of atypical IgG4-related disease presenting hypereosinophilia, polyneuropathy, and liver dysfunction. Mod Rheumatol Case Rep. 2023 Sep 26:rxad053. doi: 10.1093/mrcr/rxad053. Epub ahead of print. Erratum in: Mod Rheumatol Case Rep. 2023 Dec 01;: PMID: 37750557.
24. Murakami K, Watanabe R, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Hashimoto M, Morinobu A. Predictive value of baseline concomitant glucocorticoid for abatacept-mediated long-term inhibition of radiographic progression: insights from the KURAMA cohort. Immunol Med. 2023 Oct 3:1-7. doi: 10.1080/25785826.2023.2265148. Epub ahead of print. PMID: 37789658.
25. Onishi A, Yamada H, Yamamoto W, Watanabe R, Hara R, Katayama M, Okita Y, Maeda Y, Amuro H, Son Y, Yoshikawa A, Hata K, Hashimoto M, Saegusa J, Morinobu A. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. Rheumatology (Oxford). 2023 Nov 21:kead620. doi: 10.1093/rheumatology/kead620. Epub ahead of print. PMID: 37988163.
26. Okuma K, Oku T, Sasaki C, Kitagori K, Mimori T, Aramori I, Hirayama Y, Yoshifuji H. Similarity and difference between systemic lupus erythematosus and NZB/W F1 mice by multi-omics analysis. Mod Rheumatol. 2023 Mar 3:road024. doi: 10.1093/mr/road024. Epub ahead of print. PMID: 36869711.
27. Yoshifuji H, Yomono K, Yamano Y, Kondoh Y, Yasuoka H. Role of rituximab in the treatment of systemic sclerosis: A literature review. Mod Rheumatol. 2023 Nov 1;33(6):1068-1077. doi: 10.1093/mr/road040. PMID: 37053127.
28. Sugihara T, Yoshifuji H, Uchida HA, Maejima Y, Watanabe Y, Tanemoto K, Umezawa N, Manabe Y, Ishizaki J, Shirai T, Nagafuchi H, Hasegawa H, Niiro H, Ishii T, Nakaoka Y, Harigai M. Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. Mod Rheumatol. 2023 May 24:road046. doi: 10.1093/mr/road046. Epub ahead of print. PMID: 37225423.
29. Yamazaki S, Izawa K, Matsushita M, Moriichi A, Kishida D, Yoshifuji H, Yamaji K, Nishikomori R, Mori M, Miyamae T. Promoting awareness of terminology related to unmet medical needs in context of rheumatic diseases in Japan: a systematic review for evaluating unmet medical needs. Rheumatol Int. 2023 Nov;43(11):2021-2030. doi: 10.1007/s00296-023-05425-z. Epub 2023 Aug 19. PMID: 37597057.
30. Nakaizumi H, Kambe N, Irie H, Kaku Y, Fujimoto M, Yoshifuji H, Kazuma Y, Katagiri K, Kanekura T, Kabashima K. Neutrophilic epitheliotropism, proposed as an auto-inflammatory condition of neutrophilic urticarial dermatosis including Schnitzler syndrome, is also observed in Japanese cases. J Dermatol. 2023 Dec 6. doi: 10.1111/1346-8138.17067. Epub ahead of print. PMID: 38057948.
31. Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, Isobe M, Harigai M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Organ Damage and Quality of Life in Takayasu Arteritis　- Evidence From a National Registry Analysis. Circ J. 2023 Dec 19. doi: 10.1253/circj.CJ-23-0656. Epub ahead of print. PMID: 38123296.
32. Yamamoto S, Wells K, Morita K, Tanigaki K, Muro K, Matsumoto M, Nakai H, Arai Y, Akizuki S, Takahashi K, Minamiguchi S, Fukuma S, Yanagita M. Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review. Intern Med. 2023 Sep 15;62(18):2715-2724. doi: 10.2169/internalmedicine.1178-22. Epub 2023 Feb 1. PMID: 36725034; PMCID: PMC10569924.
33. Tanaka A, Maeda S, Nomura T, Llamas-Covarrubias MA, Tanaka S, Jin L, Lim EL, Morikawa H, Kitagawa Y, Akizuki S, Ito Y, Fujimori C, Hirota K, Murase T, Hashimoto M, Higo J, Zamoyska R, Ueda R, Standley DM, Sakaguchi N, Sakaguchi S. Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease. J Exp Med. 2023 Feb 6;220(2):e20220386. doi: 10.1084/jem.20220386. Epub 2022 Dec 1. PMID: 36454183; PMCID: PMC9718937.
34. Kotani T, Matsuda S, Okazaki A, Nishioka D, Watanabe R, Gon T, Manabe A, Shoji M, Kadoba K, Hiwa R, Yamamoto W, Hashimoto M, Takeuchi T. Risk prediction model for mortality in microscopic polyangiitis: multicentre REVEAL cohort study. Arthritis Res Ther. 2023 Nov 20;25(1):223. doi: 10.1186/s13075-023-03210-8. PMID: 37986108; PMCID: PMC10658814.
35. Matsuda S, Kotani T, Okazaki A, Nishioka D, Watanabe R, Gon T, Manabe A, Shoji M, Kadoba K, Hiwa R, Yamamoto W, Hashimoto M, Takeuchi T. Prediction model for respiratory-related mortality in microscopic polyangiitis with interstitial lung disease: multicenter REVEAL cohort study. Rheumatology (Oxford). 2023 Aug 26:kead444. doi: 10.1093/rheumatology/kead444. Epub ahead of print. PMID: 37632776.
36. Yaku A, Ishikawa Y, Iwasaki T, Hiwa R, Matsuo K, Saji H, Yurugi K, Miura Y, Furu M, Ito H, Fujii T, Maekawa T, Hashimoto M, Ohmura K, Mimori T, Terao C. Genetic architecture underlying IgG-RF production is distinct from that of IgM-RF. Rheumatology (Oxford). 2023 May 2;62(5):2015-2020. doi: 10.1093/rheumatology/keac593. PMID: 36250908.

2022年

1. Kojima M, Kawahito Y, Sugihara T, Kojima T, Harada R, Hirata S, Hashimoto M, Hidaka T, Ishikawa H, Ito H, Kishimoto M, Kaneko Y, Matsui K, Matsui T, Matsushita I, Morinobu A, Nishida K, Tanaka E, Abe A, Ishitoku M, Asai S, Kida T, Onishi A, Takanashi S, Harigai M. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design. BMC Rheumatol. 2022 Dec 26;6(1):90. doi: 10.1186/s41927-022-00322-7. PMID: 36567352; PMCID: PMC9791765.
2. Takase Y, Shirakashi M, Nishida Y, Katsushima M, Onizawa H, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Onishi A, Nakashima R, Murakami K, Yoshifuji H, Tanaka M, Tsuruyama T, Morinobu A, Hashimoto M. Enteric Toll-like receptor 7 stimulation causes acute exacerbation in lupus-susceptible mice. Clin Rheumatol. 2022 Dec 14. doi: 10.1007/s10067-022-06467-7. Epub ahead of print. PMID: 36515794.
3. Sasai T, Nakashima R, Shirakashi M, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Yoshifuji H, Mimori T, Morinobu A. A new autoantibody to valyl transfer RNA synthetase associated with anti-synthetase syndrome. Rheumatology (Oxford). 2022 Oct 4:keac569. doi: 10.1093/rheumatology/keac569. Epub ahead of print. PMID: 36193992.
4. Sugimoto A, Fujimoto M, Fujii H, Takeuchi Y, Hirata M, Usui S, Nakamizo S, Ikezoe K, Ikeo S, Yamada Y, Minamiguchi S, Morinobu A, Haga H. Fatal case of methotrexate-associated primary cutaneous extranodal NK/T-cell lymphoma of gamma delta phenotype. Histopathology. 2022 Dec;81(6):849-852. doi: 10.1111/his.14792. Epub 2022 Sep 19. PMID: 36093627.
5. Katsushima M, Minamino H, Shirakashi M, Onishi A, Fujita Y, Yamamoto W, Onizawa H, Tsuji H, Watanabe R, Murakami K, Fujii T, Murata K, Tanaka M, Inagaki N, Morinobu A, Hashimoto M. High plasma homocysteine level is associated with increased prevalence of non-remission state in rheumatoid arthritis: findings from the KURAMA cohort. Mod Rheumatol. 2022 Sep 7:roac106. doi: 10.1093/mr/roac106. Epub ahead of print. PMID: 36069659.
6. Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Morita S, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y, Takeuchi O. Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages. Circulation. 2022 Sep 27;146(13):1006-1022. doi: 10.1161/CIRCULATIONAHA.122.059435. Epub 2022 Aug 23. Erratum in: Circulation. 2022 Nov 8;146(19):e280. PMID: 35997026.
7. Masui S, Yonezawa A, Yokoyama K, Iwamoto N, Shimada T, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Nakagawa S, Hira D, Itohara K, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K. N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4. Pharm Res. 2022 Oct;39(10):2541-2554. doi: 10.1007/s11095-022-03371-2. Epub 2022 Aug 19. PMID: 35986123.
8. Yoshida T, Tsuji H, Onishi A, Takase Y, Shirakashi M, Onizawa H, Hiwa R, Kitagori K, Akizuki S, Nakashima R, Tanaka M, Yoshifuji H, Morinobu A. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022 Aug;9(1):e000727. doi: 10.1136/lupus-2022-000727. PMID: 35961691; PMCID: PMC9378947.
9. Tabuchi Y, Katsushima M, Nishida Y, Shirakashi M, Tsuji H, Onizawa H, Kitagori K, Akizuki S, Nakashima R, Murakami K, Murata K, Yoshifuji H, Tanaka M, Morinobu A, Hashimoto M. Oral dextran sulfate sodium administration induces peripheral spondyloarthritis features in SKG mice accompanied by intestinal bacterial translocation and systemic Th1 and Th17 cell activation. Arthritis Res Ther. 2022 Jul 25;24(1):176. doi: 10.1186/s13075-022-02844-4. PMID: 35879738; PMCID: PMC9310491.
10. Iwasaki T, Watanabe R, Ito H, Fujii T, Okuma K, Oku T, Hirayama Y, Ohmura K, Murata K, Murakami K, Yoshitomi H, Tanaka M, Matsuda S, Matsuda F, Morinobu A, Hashimoto M. Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis. Front Immunol. 2022 Jun 6;13:901437. doi: 10.3389/fimmu.2022.901437. PMID: 35734167; PMCID: PMC9208293.
11. Yoshida T, Yoshifuji H, Shirakashi M, Nakakura A, Murakami K, Kitagori K, Akizuki S, Nakashima R, Ohmura K, Morinobu A. Risk factors for the recurrence of relapsing polychondritis. Arthritis Res Ther. 2022 May 30;24(1):127. doi: 10.1186/s13075-022-02810-0. PMID: 35637525; PMCID: PMC9150329.
12. Fukui A, Nakayama Y, Yoshida T, Murakami K, Kadoba K, Onizawa H, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Sugimoto A, Yamamoto S, Morinobu A. A case of intestinal amoebiasis mimicking intestinal Behçet’s disease. Mod Rheumatol Case Rep. 2022 Jun 24;6(2):270-272. doi: 10.1093/mrcr/rxac028. PMID: 35388431.
13. Law SM, Akizuki S, Morinobu A, Ohmura K. A case of refractory systemic lupus erythematosus with monocytosis exhibiting somatic KRAS mutation. Inflamm Regen. 2022 Apr 1;42(1):10. doi: 10.1186/s41232-022-00195-w. PMID: 35361277; PMCID: PMC8973904.
14. Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, Seto Y, Sugihara T, Tanaka E, Ito H, Kojima T, Matsushita I, Nishida K, Mori M, Murashima A, Yamanaka H, Nakayama T, Kojima M, Harigai M. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol. 2023 Jan 3;33(1):21-35. doi: 10.1093/mr/roac017. PMID: 35297492.
15. Ito H, Nishida K, Kojima T, Matsushita I, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Yamanaka H, Kawahito Y, Harigai M. Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol. 2023 Jan 3;33(1):36-45. doi: 10.1093/mr/roac019. PMID: 35294030.
16. Nakayama Y, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A, Hashimoto M. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatol Int. 2022 Jul;42(7):1227-1234. doi: 10.1007/s00296-021-05086-w. Epub 2022 Mar 10. PMID: 35266034.
17. Shinkawa Y, Imami K, Fuseya Y, Sasaki K, Ohmura K, Ishihama Y, Morinobu A, Iwai K. ABIN1 is a signal-induced autophagy receptor that attenuates NF-κB activation by recognizing linear ubiquitin chains. FEBS Lett. 2022 May;596(9):1147-1164. doi: 10.1002/1873-3468.14323. Epub 2022 Mar 4. PMID: 35213742.
18. Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4445-4454. doi: 10.1093/rheumatology/keac101. PMID: 35179548.
19. Yamaguchi E, Kadoba K, Watanabe R, Iwasaki T, Kitagori K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Tanaka M, Morinobu A, Yoshifuji H. Clinical profile and outcome of large-vessel giant cell arteritis in Japanese patients: A single-centre retrospective cohort study. Mod Rheumatol. 2023 Jan 3;33(1):175-181. doi: 10.1093/mr/roac013. PMID: 35141755.
20. Tsuji H, Kuramoto N, Sasai T, Shirakashi M, Onizawa H, Kitagori K, Akizuki S, Nakashima R, Watanabe R, Onishi A, Murakami K, Yoshifuji H, Tanaka M, Hashimoto M, Ohmura K, Morinobu A. Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis. Rheumatology (Oxford). 2022 Oct 6;61(10):4130-4135. doi: 10.1093/rheumatology/keac047. PMID: 35078211.
21. Doi K, Murata K, Ito S, Suzuki A, Terao C, Ishie S, Umemoto A, Murotani Y, Nishitani K, Yoshitomi H, Fujii T, Watanabe R, Hashimoto M, Murakami K, Tanaka M, Ito H, Park-Min KH, Ivashkiv LB, Morinobu A, Matsuda S. Role of Lysine-Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia-Inducible Factor 1α and E2F1. Arthritis Rheumatol. 2022 Jun;74(6):948-960. doi: 10.1002/art.42074. Epub 2022 Apr 27. PMID: 35077015; PMCID: PMC9156537.
22. Matsuo T, Sasai T, Nakashima R, Kuwabara Y, Kato ET, Murakami I, Onizawa H, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Tanaka M, Morinobu A, Mimori T. ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis. Front Immunol. 2022 Jan 7;12:765140. doi: 10.3389/fimmu.2021.765140. PMID: 35069538; PMCID: PMC8776991.
23. Ma S, Murakami K, Tanaka K, Hashimoto M, Tanaka M, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Morinobu A, Mimori T. Fatostatin ameliorates inflammation without affecting cell viability. FEBS Open Bio. 2022 Mar;12(3):594-604. doi: 10.1002/2211-5463.13364. Epub 2022 Feb 1. PMID: 35015380; PMCID: PMC8886327.
24. Murata K, Uozumi R, Hashimoto M, Ebina K, Akashi K, Onishi A, Nagai K, Yoshikawa A, Katayama M, Son Y, Amuro H, Hara R, Yamamoto W, Watanabe R, Murakami K, Tanaka M, Ito H, Morinobu A, Matsuda S. The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study. Mod Rheumatol. 2022 Jul 1;32(4):834-838. doi: 10.1093/mr/roab043. PMID: 34910199.
25. Ma S, Murakami K, Saito R, Ito H, Murata K, Nishitani K, Hashimoto M, Tanaka M, Taniguchi M, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Morinobu A, Mimori T. Increased Ratio of CD14⁺⁺CD80⁺ Cells/CD14⁺⁺CD163⁺ Cells in the Infrapatellar Fat Pad of End-Stage Arthropathy Patients. Front Immunol. 2021 Nov 26;12:774177. doi: 10.3389/fimmu.2021.774177. PMID: 34899727; PMCID: PMC8662627.
26. Iwasaki T, Doi H, Tsuji H, Tabuchi Y, Hashimoto M, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Yamamoto W, Tanaka M, Ohmura K, Morinobu A. Phenotypic landscape of systemic lupus erythematosus: An analysis of the Kyoto Lupus Cohort. Mod Rheumatol. 2022 Apr 18;32(3):571-576. doi: 10.1093/mr/roab020. PMID: 34894258.
27. Mukoyama H, Shirakashi M, Tanaka N, Iwasaki T, Nakajima T, Onizawa H, Tsuji H, Kitagori K, Akizuki S, Nakashima R, Murakami K, Tanaka M, Morinobu A, Yoshifuji H. The clinical features of pulmonary artery involvement in Takayasu arteritis and its relationship with ischemic heart diseases and infection. Arthritis Res Ther. 2021 Dec 3;23(1):293. doi: 10.1186/s13075-021-02675-9. PMID: 34857042; PMCID: PMC8641170.
28. Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E. Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE). PLoS One. 2021 Nov 15;16(11):e0259389. doi: 10.1371/journal.pone.0259389. PMID: 34780502; PMCID: PMC8592402.
29. Yoshida T, Hashimoto M, Horiguchi G, Murakami K, Murata K, Nishitani K, Watanabe R, Yamamoto W, Tanaka M, Morinobu A, Ito H, Matsuda S, Uehara R. Pain catastrophizing hinders Disease Activity Score 28 – erythrocyte sedimentation rate remission of rheumatoid arthritis in patients with normal C-reactive protein levels. Int J Rheum Dis. 2021 Dec;24(12):1520-1529. doi: 10.1111/1756-185X.14231. Epub 2021 Oct 26. PMID: 34698449.
30. Minamino H, Katsushima M, Torii M, Yamamoto W, Fujita Y, Ikeda K, Okamura E, Murakami K, Watanabe R, Murata K, Ito H, Tanaka M, Arai H, Matsuda S, Morinobu A, Inagaki N, Hashimoto M. Serum vitamin D status inversely associates with a prevalence of severe sarcopenia among female patients with rheumatoid arthritis. Sci Rep. 2021 Oct 14;11(1):20485. doi: 10.1038/s41598-021-99894-6. PMID: 34650186; PMCID: PMC8516961.

2021年

1. Yoshifuji H, Kagebayashi S, Kinoshita H, Fujii T, Okano Y, Katsushima M, Mimori T. A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. Immunol Med. 2021 Jan 15:1-7. doi: 10.1080/25785826.2021.1874137. Online ahead of print.
2. Kamioka H, Mori Y, Horiuchi T, Hayashi T, Ohmura K, Yamaguchi S, Kato M. Association of Daily Home-Based Hot Water Bathing and Glycemic Control in Ambulatory Japanese Patients with Type 2 Diabetes Mellitus During the COVID-19 Pandemic: A Multicenter Cross-Sectional Study. Diabetes Metab Syndr Obes. 2020 Dec 22;13:5059-5069. doi: 10.2147/DMSO.S279270. eCollection 2020.
3. Rose E, Ferrada MA, Quinn KA, Goodspeed W, Arnaud L, Sharma A, Yoshifuji H, Kim J, Allen C, Sirajuddin A, Chen M, Grayson PC.Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. Arthritis Care Res (Hoboken). 2021 Feb 5. doi: 10.1002/acr.24574. Online ahead of print.
4. Itaya T, Torii M, Hashimoto M, Tanigawa K, Urai Y, Kinoshita A, Nin K, Jindai K, Watanabe R, Murata K, Murakami K, Tanaka M, Ito H, Matsuda S, Morinobu A. Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic. Rheumatology (Oxford). 2021 Jan 27:keab065. doi: 10.1093/rheumatology/keab065. Online ahead of print.
5. Nihira H, Izawa K, Ito M, Umebayashi H, Okano T, Kajikawa S, Nanishi E, Keino D, Murakami K, Isa-Nishitani M, Shiba T, Honda Y, Hijikata A, Yasu T, Kubota T, Hasegawa Y, Kawashima Y, Nakano N, Takada H, Ohga S, Heike T, Takita J, Ohara O, Takei S, Takahashi M, Kanegane H, Morio T, Iwaki-Egawa S, Sasahara Y, Nishikomori R, Yasumi T. Detailed Analysis of Japanese Patients with Adenosine Deaminase 2 Deficiency Reveals Characteristic Elevation of Type II Interferon Signature and STAT1 Hyperactivation. J Allergy Clin Immunol. 2021 Jan 30:S0091-6749(21)00157-3. doi: 10.1016/j.jaci.2021.01.018. Online ahead of print.
6. Kadoba K, Watanabe R, Hashimoto M, Morinobu A, Terao C, Yoshifuji H. Rheumatology (Oxford). Comment on: Different treatment options for Takayasu arteritis patients with moderate-to-severe aortic regurgitation: long-term outcomes.2021 Feb 22:keab184. 
7. Minamino H, Katsushima M, Torii M, Hashimoto M, Fujita Y, Ikeda K, Yamamoto W, Watanabe R, Murakami K, Murata K, Nishitani K, Tanaka M, Ito H, Ohmura K, Arai H, Inagaki N, Matsuda S.  Habitual fish intake negatively correlates with prevalence of frailty among patients with rheumatoid arthritis. Sci Rep. 2021 Mar 3;11(1):5104. doi: 10.1038/s41598-021-84479-0.
8. Minamino H, Katsushima M, Hashimoto M, Fujita Y, Yoshida T, Ikeda K, Isomura N, Oguri Y, Yamamoto W, Watanabe R, Murakami K, Murata K, Nishitani K, Tanaka M, Ito H, Ohmura K, Matsuda S, Inagaki N, Morinobu A.Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2021 Mar 27;23(1):96. doi: 10.1186/s13075-021-02479-x.
9. Doi H, Ohmura K, Tabuchi Y, Hashimoto M, Takase Y, Inaba R, Kozuki T, Iwasaki T, Taniguchi M, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Yamamoto W, Tanaka M, Akio M. Validation and verification of the Japanese version of the systemic lupus erythematosus symptom checklist for patient quality of life. Lupus. 2021 Mar 28:9612033211005026. doi: 10.1177/09612033211005026.
10. Sugihara T, Kawahito Y, Morinobu A, Kaneko Y, Seto Y, Kojima T, Ito H, Kohno M, Nakayama T, Sobue Y, Nishida K, Matsushita I, Murashima A, Mori M, Tanaka E, Hirata S, Kishimoto M, Yamanaka H, Kojima M, Harigai M. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2021 May 19:1-15. doi: 10.1080/14397595.2021.1912922. 
11. Kojima M, Hasegawa M, Hirata S, Ito H, Kaneko Y, Kishimoto M, Kohno M, Kojima T, Matsushita I, Mori M, Morinobu A, Murashima A, Nishida K, Seto Y, Sobue Y, Sugihara T, Tanaka E, Nakayama T, Kawahito Y, Harigai M. Patients’ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Mod Rheumatol. 2021 May 19:1-6. doi: 10.1080/14397595.2021.1913276.
12. Ito H, Murata K, Sobue Y, Kojima T, Nishida K, Matsushita I, Kawahito Y, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Harigai M.Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2021 Apr 15:1-25. doi: 10.1080/14397595.2021.1913824.
13. Onishi A, Akashi K, Yamamoto W, Ebina K, Murata K, Hara R, Katayama M, Nagai K, Hirano T, Amuro H, Son Y, Yamamoto K, Hashimoto M, Morinobu A.The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study. Am J Kidney Dis. 2021 May 10:S0272-6386(21)00577-1. doi: 10.1053/j.ajkd.2021.02.338. 
14. Matsuo H, Tabuchi Y, Yukimatsu R, Imamura A, Shimizu M, Inagaki M, Tsuji Y, Nakabo S, Tsuji H, Nakajima T, Hashimoto M, Ito H, Morinobu A, Fujii Y Positive rate and prognostic significance of the superb microvascular imaging signal in joints of rheumatoid arthritis patients in remission with normal C-reactive protein levels and erythrocyte sedimentation rates. J Med Ultrason (2001). 2021 May 20. doi: 10.1007/s10396-021-01102-5.
15. Ota M, Nagafuchi Y, Hatano H, Ishigaki K, Terao C, Takeshima Y, Yanaoka H, Kobayashi S, Okubo M, Shirai H, Sugimori Y, Maeda J, Nakano M, Yamada S, Yoshida R, Tsuchiya H, Tsuchida Y, Akizuki S, Yoshifuji H, Ohmura K, Mimori T, Yoshida K, Kurosaka D, Okada M, Setoguchi K, Kaneko H, Ban N, Yabuki N, Matsuki K, Mutoh H, Oyama S, Okazaki M, Tsunoda H, Iwasaki Y, Sumitomo S, Shoda H, Kochi Y, Okada Y, Yamamoto K, Okamura T, Fujio K. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell. 2021 Apr 21:S0092-8674(21)00429-3. doi: 10.1016/j.cell.2021.03.056. 
16. Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, Ito H, Matsuda S. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2021 May 25:1-10. doi: 10.1080/25785826.2021.1928383.
17. Suma H, Yoshida Y, Sugimoto T, Matsuo Y, Law SM, Nakashima R, Kobayashi H, Hosokawa Y, Ishitoku M, Kohno H, Watanabe H, Tokunaga T, Mokuda S, Nojima T, Hirata S, Sugiyama E. The clinical characteristics and predictors of severe digital ischemia in patients with anti-aminoacyl transfer RNA synthetase antibodies.
    J Dermatol. 2021 Apr 13. doi: 10.1111/1346-8138.15884.
18. Ishie S, Ito H, Nakabo S, Tsuji H, Nakajima T, Tsuji Y, Inagaki M, Furu M, Hashimoto M, Murata K, Murakami K, Nishitani K, Tanaka M, Fujii Y, Matsuda S Region specificity of rheumatoid foot symptoms associated with ultrasound-detected synovitis and joint destruction. Mod Rheumatol. 2021 Apr 14:1-28. 
19. Maeda Y, Hirano T, Ebina K, Hara R, Hashimoto M, Yamamoto W, Murakami K, Kotani T, Hata K, Son Y, Amuro H, Onishi A, Jinno S, Katayama M, Kumanogoh A. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study. Rheumatol Int. 2021 Apr 26. doi: 10.1007/s00296-021-04862-y.
20. Nishisho R, Kusuhara S, Sotani N, Kim KW, Katsuyama-Yoshikawa A, Matsumiya W, Akashi K, Morinobu A, Nakamura M.Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1273-1280.
21. Sobue Y, Kojima T, Ito H, Nishida K, Matsushita I, Kaneko Y, Kishimoto M, Kohno M, Sugihara T, Seto Y, Tanaka E, Nakayama T, Hirata S, Murashima A, Morinobu A, Mori M, Kojima M, Kawahito Y, Harigai M.Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Mod Rheumatol. 2021 Mar 16:1-6. doi: 10.1080/14397595.2021.1892258. 
22. Hayashi N, Uto K, Imanishi A, Sugiyama D, Morinobu A, Saegusa J.Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. Medicine (Baltimore). 2021 Mar 5;100(9):e24556.
23. Tanaka E, Kawahito Y, Kohno M, Hirata S, Kishimoto M, Kaneko Y, Tamai H, Seto Y, Morinobu A, Sugihara T, Murashima A, Kojima M, Mori M, Ito H, Kojima T, Sobue Y, Nishida K, Matsushita I, Nakayama T, Yamanaka H, Harigai M.Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2021 Apr 6:1-13. doi: 10.1080/14397595.2021.1899591. 
24. Yamamoto Y, Okano T, Yamada H, Akashi K, Sendo S, Ueda Y, Morinobu A, Saegusa J.Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis. Arthritis Res Ther. 2021 May 3;23(1):133.
25. Takase Y, Iwasaki T, Doi H, Tsuji H, Hashimoto M, Ueno K, Inaba R, Kozuki T, Taniguchi M, Tabuchi Y, Watanabe R, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Itaya T, Yamamoto W, Uozumi R, Tanaka M, Ohmura K, Morinobu A.Correlation between irreversible organ damage and the quality of life of patients with systemic lupus erythematosus: The Kyoto Lupus Cohort survey. Lupus. 2021 Jun 14:9612033211025614. doi: 10.1177/09612033211025614.
26. Tsuji H, Ohmura K, Jin H, Naito R, Arase N, Kohyama M, Suenaga T, Sakakibara S, Kochi Y, Okada Y, Yamamoto K, Kikutani H, Morinobu A, Mimori T, Arase H. Anti-dsDNA antibodies recognize DNA presented on HLA class II molecules of systemic lupus erythematosus risk alleles.
    Arthritis Rheumatol. 2021 Jun 23. doi: 10.1002/art.41897. 
27. Kadoba K, Watanabe R, Iwasaki T, Nakajima T, Kitagori K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Tanaka M, Ohmura K, Morinobu A, Terao C, Yoshifuji H. A susceptibility locus in the IL12B but not LILRA3 region is associated with vascular damage in Takayasu arteritis. Sci Rep. 2021 Jul 1;11(1):13667. 
28. Nakajima T, Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ito H, Yamamoto W, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Matsuda S, Morinobu A.Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients. Rheumatol Int. 2021 Jul 9. doi: 10.1007/s00296-021-04944-x. 
29. Uto K, Ueda K, Okano T, Akashi K, Takahashi S, Nakamachi Y, Imanishi T, Awano H, Morinobu A, Kawano S, Saegusa J.Identification of Plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis. Rheumatology (Oxford). 2021 Jul 23:keab588. doi: 10.1093/rheumatology/keab588.
30. Minamino H, Katsushima M, Hashimoto M, Fujita Y, Torii M, Ikeda K, Isomura N, Oguri Y, Yamamoto W, Watanabe R, Murakami K, Murata K, Nishitani K, Tanaka M, Ito H, Uda M, Nin K, Arai H, Matsuda S, Morinobu A, Inagaki N.Influence of dietary habits on depression among patients with rheumatoid arthritis: A cross-sectional study using KURAMA cohort database. PLoS One. 2021 Aug 5;16(8):e0255526. doi: 10.1371/journal.pone.0255526
31. Yamada H, Saegusa J, Sendo S, Ueda Y, Okano T, Shinohara M, Morinobu A.Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis. Sci Rep. 2021 Aug 27;11(1):17312. doi: 10.1038/s41598-021-96530-1.
32. Shima A, Maki T, Mimura N, Yamashita H, Emoto N, Yoshifuji H, Takahashi R. A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus. eNeurologicalSci. 2021 Jun 16;24:100351. doi: 10.1016/j.ensci.2021.100351.
33. Takimoto-Ito R, Kambe N, Kogame T, Otsuka A, Nomura T, Izawa K, Tabuchi Y, Yoshifuji H, Takeuchi Y, Kabashima K.Refractory serum immunoglobulin M elevation during anti-interleukin (IL)-1- or IL-6-targeted treatment in four patients with Schnitzler syndrome. J Dermatol. 2021 Aug 26. doi: 10.1111/1346-8138.16124. 
34. Tanaka M.Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise. Lancet Reg Health West Pac. 2021 Apr 12;10:100144. doi: 10.1016/j.lanwpc.2021.100144. 
35. Hiwa R, Nielsen HV, Mueller JL, Mandla R, Zikherman J. NR4A family members regulate T cell tolerance to preserve immune homeostasis and suppress autoimmunity. JCI Insight. 2021 Aug 3:151005. doi: 10.1172/jci.insight.151005.
36. Takeuchi Y, Ohara D, Watanabe H, Sakaguchi N, Sakaguchi S, Kondoh G, Morinobu A, Mimori T, Hirota K. Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis. Sci Rep. 2021 Sep 21;11(1):18679. doi: 10.1038/s41598-021-98145-y.
37. Itaya T, Torii M, Hashimoto M, Jindai K, Yamamoto W, Tanigawa K, Urai Y, Kinoshita A, Nin K, Watanabe R, Murata K, Murakami K, Tanaka M, Ito H, Matsuda S, Morinobu A. Perceptions and behaviours related to COVID-19 in patients with rheumatoid arthritis: a cross-sectional study. Clin Rheumatol. 2021 Sep 28:1-7. doi: 10.1007/s10067-021-05840-2. Online ahead of print.

2020年

1. 1. Niwamoto T, Handa T, Matsui S, Yamamoto H, Yoshifuji H, Abe H, Matsumoto H, Kodama Y, Chiba T, Seno H, Mimori T, Hirai T. Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis. Mod Rheumatol. 2020 Jan 4:1-6. doi: 10.1080/14397595.2019.1703522. [Epub ahead of print]
   2. Murakami I, Murakami K, Hashimoto M, Tanaka M, Ito H, Fujii T, Torii M, Ikeda K, Kuwabara A, Tanaka K, Yoshida A, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Usui T, Morita S, Mimori T.  Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. PLoS One. 2020 Feb 13;15(2):e0228852. doi: 10.1371/journal.pone.0228852. eCollection 2020.
   3. Nakabo S, Tsuji Y, Inagaki M, Tsuji H, Nakajima T, Murakami K, Terao C, Hashimoto M, Furu M, Tanaka M, Ito H, Fujii T, Mimori T, Fujii Y.  Severe joint deformity and patient global assessment of disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients. Mod Rheumatol. 2020 May 5:1-9. doi: 10.1080/14397595.2020.1751922. [Epub ahead of print]
   4. Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Ohmura K, Mimori T.  Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020 Apr 10. pii: keaa123. doi: 10.1093/rheumatology/keaa123. [Epub ahead of print]
   5. Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D,Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki H, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2020 Jan 7:1-5. 
   6. Minamino H, Katsushima M, Yoshida T, Hashimoto M, Fujita Y, Shirakashi M, Yamamoto W, Murakami K, Murata K, Nishitani K, Tanaka M, Ito H, Inagaki N, Matsuda S. Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database. PLoS One. 2020 Mar 3;15(3):e0229998.
   7. Sugihara T, Hasegawa H, Uchida HA,Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS).Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther. 2020 Apr 7;22(1):72.
   8. Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takihara K, Murohara T, Momomura SI; JCS Joint Working Group.JCS 2017 Guideline on Management of Vasculitis Syndrome- Digest Version. Circ J. 2020 Jan 24;84(2):299-359.
   9. Ohmura K. Which Is the Best SLE Activity Index for Clinical Trials? Mod Rheumatol. 2020 May 30;1-23. doi: 10.1080/14397595.2020.1775928.
   10. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S,Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N.Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020 Jan 17:kez630.
   11. Nakayama Y,Taura D,Shibue K, Kuramoto N, Mimori T, Inagaki N. A case of systemic lupus erythematosus complicated by subclinical Cushing’s syndrome: case report. Modern Rheumatology Case Reports,Volume 4, 2020 – Issue 1
   12. Ishibashi M, Honda T, Tabuchi Y,  Kabashima K. Polyenthesitis during treatment with dupilumab for atopic dermatitis.  J Eur Acad Dermatol Venereol. 2020 Jan 28. doi: 10.1111/jdv.16239. [Epub ahead of print]
   13. Yoshifuji H, Chikashi T. Roles of cytotoxic lymphocytes and MIC/LILR families in pathophysiology of Takayasu arteritis.Inflammation and Regeneration. 2020, doi.org/10.1186/s41232-020-00119-6
   14. Korogi Y, Tanaka N, Yoshifuji H, Tazaki J, Kubo T, Tanizawa K.Complete occlusion of right pulmonary artery in Behcet disease. Respirology Case Reports 8(6), 2020, e00594
   15. Gon Y, Yoshifuji H, Nakajima T, Murakami K, Nakashima R, Ohmura K, Mimori T, Terao C. Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab.
       Mod Rheumatol. 2020 Aug 19:1-6. doi: 10.1080/14397595.2020.1800560. Online ahead of print.
   16. Kondo-Ishikawa S, Fujii T, Ishigooka N, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Ohmura K, Mimori T.Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus.
       Lupus. 2020 Sep 3:961203320954918. doi: 10.1177/0961203320954918. Online ahead of print.
   17. Yamazaki K, Minatoya K, Sakamoto K, Kitagori K, Okuda M,Murakami K. Hypothermic circulatory arrest for aortic dissection with cryoglobulinemia.
        J Card Surg. 2020 Jul 28. doi: 10.1111/jocs.14908. Online ahead of print.
   18. Nakagami Y, Sugihara G, Nakashima N, Hazama M, Son S, Ma S, Matsumoto R, Murai T, Ikeda A, Murakami K.Anti-PDHA1 antibody is detected in a subset of patients with schizophrenia.
       Sci Rep. 2020 May 13;10(1):7906. doi: 10.1038/s41598-020-63776-0.
   19. Watanabe R,Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases.
       Ann Rheum Dis. 2020 Aug 7:annrheumdis-2020-217995. doi: 10.1136/annrheumdis-2020-217995. Online ahead of print.
   20. Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W, Murata K, Takeuchi T, Kotani T, Maeda Y, Ebina K, Son Y, Amuro H, Hara R, Katayama M, Saegusa J, Morinobu A.Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.
       Rheumatol Int. 2020 Jul 29. doi: 10.1007/s00296-020-04660-y. Online ahead of print.
   21. Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM.    Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences.
       Curr Rheumatol Rep. 2020 Aug 26;22(10):68. doi: 10.1007/s11926-020-00948-x.
   22. Watanabe R, Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases.
       Ann Rheum Dis. 2020 Aug 7:annrheumdis-2020-217995. doi: 10.1136/annrheumdis-2020-217995.
   23. Watanabe R.Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
       Rheumatology (Oxford). 2020 Sep 1;59(9):e46-e47. doi: 10.1093/rheumatology/keaa253.
   24. Watanabe R. JAK inhibitors as promising agents for refractory Takayasu arteritis.
       Ann Rheum Dis. 2020 Apr 27:annrheumdis-2020-217577. doi: 10.1136/annrheumdis-2020-217577. Online ahead of print.
   25. Takeuchi Y, Hirota K, Sakaguchi S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells.
       Front Immunol. 2019 Aug 21;10:1989. doi: 10.3389/fimmu.2019.01989. eCollection 2019. 
   26. Tsuji H, Yoshifuji H, Shindo T, Hishizawa M, Ishida A, Fujimoto M, Kitagori K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Tanaka M, Ohmura K. Primary hepatic lymphoma as other iatrogenic immunodeficiency-related lymphoproliferative disorders: a case report and review of the literature. Mod Rheumatol Case Rep. 2020 Sep 28:1-12. doi: 10.1080/24725625.2020.1826627.
   27. Onizawa H, Kato H, Kimura H, Kudo T, Soda N, Shimizu S, Funabiki M, Yagi Y, Nakamoto Y, Priller J, Nishikomori R, Heike T, Yan N, Tsujimura T,Mimori T, Fujita T. Aicardi-Goutières syndrome-like encephalitis in mutant mice with constitutively active MDA5. Int Immunol. 2020 Nov 9:dxaa073. doi: 10.1093/intimm/dxaa073.
   28. Iwasaki T, Nakabo S, Terao C, Murakami K, Nakashima R, Hashimoto M, Imura Y, Yukawa N, Yoshifuji H, Miura Y, Yurugi K, Maekawa T, van Delft MAM, Trouw LA, Fujii T, Mimori T,Ohmura K. Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. Arthritis Res Ther. 2020 Oct 19;22(1):248. doi: 10.1186/s13075-020-02351-4.
   29. Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Laurynenka V, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang Y, Amano K, Park DJ, Yang W, Tada Y, Yamaji K, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, Kottyan LC, Weirauch MT, Parameswaran S, Eswar S, Salim H, Chen X, Yamamoto K, Harley JB, Ohmura K, Kim TH, Yang S, Yamamoto T, Kim BJ, Shen N, Ikegawa S, Lee HS, Zhang X, Terao C, Cui Y, Bae SC. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis. 2020 Dec 3:annrheumdis-2020-219209. doi: 10.1136/annrheumdis-2020-219209. Online ahead of print.
   30. Murata K, Ito H, Hashimoto M,Murakami K, Watanabe R, Tanaka M, Yamamoto W, Matsuda S.Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort.
       Arthritis Res Ther. 2020 Nov 12;22(1):268. doi: 10.1186/s13075-020-02366-x.
   31. Kida D, Takahashi N, Kaneko A, Hirano Y, Fujibayashi T, Kanayama Y, Hanabayashi M, Yabe Y, Takagi H, Oguchi T, Kato T, Funahashi K, Matsumoto T, Ando M, Kuwatsuka Y, Tanaka E, Yasuoka H, Kaneko Y, Hirata S,Murakami K, Sobue Y, Nishiume T, Suzuki M, Yokota Y, Terabe K, Asai S, Ishiguro N, Kojima T. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
       Sci Rep. 2020 Nov 12;10(1):19717. doi: 10.1038/s41598-020-76842-4.
   32. Tanaka N, Terao C, Nakayama Y, Sasai T, Umezawa N, Yagyu Y, Ito K, Koike R,Nakashima R, Hatta K, Mizoguchi F. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease disguising as anti-synthetase syndrome.
       Rheumatology (Oxford). 2020 Oct 24:keaa507. doi: 10.1093/rheumatology/keaa507. 
   33. Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM.Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol. 2020 Sep 25;11:587089.
   34. Nakatsuka Y, Yaku A, Handa T, Vandenbon A, Hikichi Y, Motomura Y, Sato A, Yoshinaga M, Tanizawa K, Watanabe K, Hirai T, Chin K, Suzuki Y, Uehata T, Mino T, Tsujimura T, Moro K, Takeuchi O.Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by Regnase-1.
       Eur Respir J. 2020 Sep 25:2000018. doi: 10.1183/13993003.00018-2020. 
   35. Watanabe R, Hashimoto M, Morinobu A. Correspondence on ‘The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series’. Ann Rheum Dis. 2020 Nov 3:annrheumdis-2020-219270.
   36. Kadoba K, Waki D, Nishimura K, Mukoyama H, Saito R, Murabe H, Yokota T. Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
       Medicine (Baltimore). 2020 Oct 16;99(42):e22793. doi: 10.1097/MD.0000000000022793.
   37. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study.
       Mod Rheumatol. 2020 Dec 7:1-14. doi: 10.1080/14397595.2020.1847775. Online ahead of print.
   38. Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: A multi-center retrospective cohort study. Mod Rheumatol. 2020 Dec 18:1-21. doi: 10.1080/14397595.2020.1866837. Online ahead of print.

2019年

1. Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050. doi: 10.1073/pnas.1808850115. Epub 2018 Nov 29.
2. Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J Dermatol. 2019 Jan;46(1):e1-e18. doi: 10.1111/1346-8138.14604. Epub 2018 Dec 18.
3. Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. J Rheumatol. 2019 Jan 15. pii: jrheum.180778. doi: 10.3899/jrheum.180778. [Epub ahead of print]
4. Mimori T. IgG4-related disease – a new disease entity developed in the 21st century. Mod Rheumatol. 2019 Jan 24:1-2. doi: 10.1080/14397595.2019.1573789. [Epub ahead of print] No abstract available.
5. Akizuki S, Ishigaki K, Kochi Y, Law SM, Matsuo K, Ohmura K, Suzuki A, Nakayama M, Iizuka Y, Koseki H, Ohara O, Hirata J, Kamatani Y, Matsuda F, Sumida T, Yamamoto K, Okada Y, Mimori T, Terao C. PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Ann Rheum Dis. 2019 Jan 24. pii: annrheumdis-2018-214116. doi: 10.1136/annrheumdis-2018-214116. [Epub ahead of print]
6. Kitagori K, Yoshifuji H, Oku T, Ayaki T, Kuzuya A, Nakajima T, Akizuki S, Nakashima R, Murakami K, Ohmura K, Hirayama Y, Takahashi R, Mimori T. Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus. Lupus. 2019 Mar;28(3):414-422. doi: 10.1177/0961203319828818. Epub 2019 Feb 11.
7. Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE, Rönnelid J. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2019 Jun;78(6):858-860. doi: 10.1136/annrheumdis-2018-214690. Epub 2019 Feb 13.
8. Nakabo S, Ohmura K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Mimori T. Activated neutrophil carbamylates albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis. Mod Rheumatol. 2019 Feb 21:1-5. doi: 10.1080/14397595.2019.1583819. [Epub ahead of print]
9. Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, Yamamoto W, Mimori T, Terao C. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Oct;49(2):204-210. doi: 10.1016/j.semarthrit.2019.02.003. Epub 2019 Feb 10.
10. Nakatsuka Y, Handa T, Nakashima R, Tanizawa K, Kubo T, Murase Y, Sokai A, Ikezoe K, Hosono Y, Watanabe K, Tokuda S, Uno K, Yoshizawa A, Tsuruyama T, Uozumi R, Nagai S, Hatta K, Taguchi Y, Mishima M, Chin K, Mimori T, Hirai T.  Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease.  Rheumatology (Oxford). 2019 Mar 8. pii: kez065. doi: 10.1093/rheumatology/kez065. [Epub ahead of print]
11. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK.  Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.  Ann Rheum Dis. 2019 Jul;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436. Epub 2019 Mar 12.
12. Mimori T.  Publishing Immunological Medicine-changing from Japanese Journal of Clinical Immunology.  Immunol Med. 2018 Mar;41(1):1. doi: 10.1080/09114300.2018.1451588. Epub 2018 Apr 4.
13. Kang EH, Go DJ, Mimori T, Lee SJ, Kwon HM, Park JW, Park MH, Song EY, Ha YJ, Lee EY, Lee YJ, Lee EB, Song YW.  Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.  Semin Arthritis Rheum. 2019 Oct;49(2):283-287. doi: 10.1016/j.semarthrit.2019.03.005. Epub 2019 Mar 9.
14. Matsuo T, Hashimoto M, Sakaguchi S, Sakaguchi N, Ito Y, Hikida M, Tsuruyama T, Sakai K, Yokoi H, Shirakashi M, Tanaka M, Ito H, Yoshifuji H, Ohmura K, Fujii T, Mimori T.  Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by Zap70 Mutation.  J Immunol. 2019 Jun 1;202(11):3161-3172. doi: 10.4049/jimmunol.1801159. Epub 2019 Apr 24.
15. Yamamoto H, Nakajima T, Kawahara R, Nakabo S, Hashimoto M, Yamamoto W, Masuda I, Ito H, Mimori T, Fujii Y.  Evaluation of risk factors for atherosclerosis using carotid ultrasonography in Japanese patients with rheumatoid arthritis.  Int J Rheum Dis. 2019 Jul;22(7):1312-1318. doi: 10.1111/1756-185X.13591. Epub 2019 May 17.
16. Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T.  The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method.  Mod Rheumatol. 2019 Jun 26:1-7. doi: 10.1080/14397595.2019.1621419. [Epub ahead of print]
17. Ishigooka N, Fujii T, Abe H, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Ito H, Ohmura K, Morita S, Mimori T.  Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis.  Mod Rheumatol. 2019 Jun 13:1-8. doi: 10.1080/14397595.2019.1621439. [Epub ahead of print]
18. Nakamura T, Satoh-Nakamura T, Nakajima A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Masaki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsui S, Saeki T, Kamisawa T, Yamamoto M, Hamano H, Origuchi T, Hirata S, Tanaka Y, Tsuboi H, Sumida T, Okazaki K, Tanaka M, Chiba T, Mimori T, Umehara H.  Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD.  Mod Rheumatol. 2019 Jul 11:1-7. doi: 10.1080/14397595.2019.1621475. [Epub ahead of print]
19. Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T.  Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.  Mod Rheumatol. 2019 Jul 22:1-10. doi: 10.1080/14397595.2019.1639931. [Epub ahead of print]
20. Tomizawa T, Ito H, Murata K, Hashimoto M, Tanaka M, Murakami K, Nishitani K, Azukizawa M, Okahata A, Doi K, Saito M, Furu M, Hamaguchi M, Mimori T, Matsuda S.  Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis.  Arthritis Res Ther. 2019 Jul 15;21(1):174. doi: 10.1186/s13075-019-1956-1.
21. Tsuji H, Hashimoto M, Harada T, Tanaka M, Ito H, Murakami K, Ohmura K, Fujii T, Mimori T.  Persistent anemia and hypoalbuminemia in rheumatoid arthritis patients with low serum triiodothyronine level.  Mod Rheumatol. 2019 Aug 8:1-8. doi: 10.1080/14397595.2019.1649109. [Epub ahead of print]
22. Okahata A, Ito H, Furu M, Ishikawa M, Fujii T, Hashimoto M, Tanaka M, Morita Y, Azukizawa M, Tomizawa T, Doi K, Nishitani K, Murata K, Yoshitomi H, Mimori T, Matsuda S.  Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor 1 Predicts the Changes of Rheumatoid Factor Titers in Rheumatoid Arthritis.  J Clin Rheumatol. 2019 Aug 6. doi: 10.1097/RHU.0000000000001116. [Epub ahead of print]
23. Ishikawa Y, Ikari K, Hashimoto M, Ohmura K, Tanaka M, Ito H, Taniguchi A, Yamanaka H, Mimori T, Terao C.  Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor.  Ann Rheum Dis. 2019 Nov;78(11):1480-1487. doi: 10.1136/annrheumdis-2019-215463. Epub 2019 Aug 19.
24. Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, Taguchi Y, Katayama M, Tanizawa K, Handa T, Uozumi R, Akizuki S, Murakami K, Hashimoto M, Tanaka M, Ohmura K, Mimori T.  A Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.  Arthritis Rheumatol. 2019 Sep 16. doi: 10.1002/art.41105. [Epub ahead of print]
25. Matsuo H, Imamura A, Shimizu M, Inagaki M, Tsuji Y, Nakabo S, Hashimoto M, Ito H, Tanaka S, Mimori T, Fujii Y.  Prediction of recurrence and remission using superb microvascular imaging in rheumatoid arthritis.  J Med Ultrason (2001). 2019 Sep 25. doi: 10.1007/s10396-019-00978-8. [Epub ahead of print]
26. Minamiyama S, Ueda S, Nakashima R, Yamakado H, Sakato Y, Yamashita H, Sawamoto N, Fujimoto R, Nishino I, Urushitani M, Mimori T, Takahashi R.  Thigh muscle MRI findings in myopathy associated with anti-mitochondrial antibody.  Muscle Nerve. 2020 Jan;61(1):81-87. doi: 10.1002/mus.26731. Epub 2019 Nov 8.
27. Kawahara R, Nakabo S, Shimizu M, Yamamoto H, Sasai T, Nishida Y, Funakoshi S, Gon Y, Taniguchi M, Nakajima T, Hiwa R, Hashimoto M, Tomizawa T, Azukizawa M, Nishitani K, Murata K, Tanaka M, Ito H, Mimori T, Fujii Y.  Feasibility of patient-oriented ultrasound joint selection: Cross-sectional observational study on rheumatoid arthritis.  Mod Rheumatol. 2019 Oct 28:1-7. doi: 10.1080/14397595.2019.1680095. [Epub ahead of print]
28. Murata K, Hashimoto M, Yamamoto W, Son Y, Amuro H, Nagai K, Takeuchi T, Katayama M, Maeda Y, Ebina K, Hara R, Jinno S, Onishi A, Murakami K, Tanaka M, Ito H, Mimori T, Matsuda S.  The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study.  Rheumatol Int. 2019 Oct 16. doi: 10.1007/s00296-019-04464-9. [Epub ahead of print]
29. Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, Sato N.  Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.  Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19.
30. Jinnin M, Ohta A, Ishihara S, Amano H, Atsumi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori A, Mimori T, Mimura T, Muro Y, Sano H, Shimizu J, Takeuchi T, Tanaka Y, Yamamoto K, Sumida T, Kohsaka H; Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare.  First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.  Ann Rheum Dis. 2019 Nov 6. pii: annrheumdis-2019-215488. doi: 10.1136/annrheumdis-2019-215488. [Epub ahead of print]
31. Doi K, Ito H, Tomizawa T, Murata K, Hashimoto M, Tanaka M, Murakami K, Nishitani K, Azukizawa M, Okahata A, Saito M, Mimori T, Matsuda S.  Oral steroid decreases the progression of joint destruction of large joints in the lower extremities in rheumatoid arthritis.  Medicine (Baltimore). 2019 Nov;98(47):e17968. doi: 10.1097/MD.0000000000017968.
32. Ohmura K. Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes.
    J Inflamm Res. 2019 Sep 17;12:259-265. 
33. Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP,Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.Version 2. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis. 2019 Aug;78(8):1055-1061. 
34. Yoshifuji H. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Mod Rheumatol. 2019 Mar;29(2):287-293
35. Chikashi Terao, Masao Ota, Takeshi Iwasaki, Masahiro Shiokawa, Shuji Kawaguchi, Katsutoshi Kuriyama, Takahisa Kawaguchi, Yuzo Kodama, Izumi Yamaguchi, Kazushige Uchida, Koichiro Higasa, Motohisa Yamamoto, Kensuke Kubota, Shujiro Yazumi, Kenji Hirano, Yasufumi Masaki, Hiroyuki Maguchi, Tomoki Origuchi, Shoko Matsui, Takahiro Nakazawa, Hideyuki Shiomi, Terumi Kamisawa, Osamu Hasebe, Eisuke Iwasaki, Kazuo Inui, Yoshiya Tanaka, Koh-ichi Ohshima, Takashi Akamizu, Shigeo Nakamura, Seiji Nakamura, Takako Saeki, Hisanori Umehara, Tooru Shimosegawa, Nobumasa Mizuno, Mitsuhiro Kawano, Atsushi Azumi, Hiroki Takahashi, Tsuneyo Mimori, Yoichiro Kamatani, Kazuichi Okazaki, Tsutomu Chiba, Shigeyuki Kawa, Fumihiko Matsuda, on behalf of the Japanese IgG4-Related Disease Working Consortium (2019). IgG4-related disease in the Japanese population: a genome-wide association study. The Lancet Rheumatology, 1(1), e14-e22.

2018年

1. Handa T, Matsui S, Yoshifuji H, Kodama Y, Yamamoto H, Minamoto S, Waseda Y, Sato Y, Kubo K, Mimori T, Chiba T, Hirai T, Mishima M. Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Mod Rheumatol. 2018 Jan 8:1-7. doi: 10.1080/14397595.2017.1416739. [Epub ahead of print]
2. Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018 Jan 13. pii: annrheumdis-2017-212149. doi: 10.1136/annrheumdis-2017-212149. [Epub ahead of print]
3. Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018 Feb 7:1-74. doi: 10.1080/14397595.2018.1438093. [Epub ahead of print] PMID: 29409370
4. Hiwa R, Ikari K, Ohmura K, Nakabo S, Matsuo K, Saji H, Yurugi K, Miura Y, Maekawa T, Taniguchi A, Yamanaka H, Matsuda F, Mimori T, Terao C. HLA-DRB1 Analysis Identified a Genetically Unique Subset within Rheumatoid Arthritis and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies. J Rheumatol. 2018 Feb 1. pii: jrheum.170363. doi: 10.3899/jrheum.170363. [Epub ahead of print]
5. Iguchi T, Takaori K, Mii A, Sato Y, Suzuki Y, Yoshifuji H, Seno H, Ogawa O, Omori K, Bessho K, Kondo S, Yoshizaki T, Nakashima H, Saito T, Mimori T, Haga H, Kawano M, Yanagita M. Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease. Mod Pathol. 2018 Feb 12. doi: 10.1038/s41379-018-0036-4. [Epub ahead of print]
6. Morita Y, Ito H, Torii M, Hanai A, Furu M, Hashimoto M, Tanaka M, Azukizawa M, Arai H, Mimori T, Matsuda S. Factors affecting walking ability in female patients with rheumatoid arthritis. PLoS One. 2018 Mar 27;13(3):e0195059. doi: 10.1371/journal.pone.0195059. eCollection 2018.
7. Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Yamamoto K, Ikeuchi S, Kushimoto S, Koike T. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol. 2018 Apr 27:1-10. doi: 10.1080/14397595.2018.1460230. [Epub ahead of print] 
8. Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H; ABROAD study investigators. Predictive factors for structural remission using abatacept: Results from the ABROAD study. Mod Rheumatol. 2018 Jun 27:1-7. doi: 10.1080/14397595.2018.1482609. [Epub ahead of print]
9. Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report. Rheumatol Int. 2018 Sep;38(9):1679-1689. doi: 10.1007/s00296-018-4095-0. Epub 2018 Jul 4.
10. Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018 Jul 6;8(1):10262. doi: 10.1038/s41598-018-28405-x.
11. Tanaka Y, Mimori T, Yamanaka H, Nakajima R, Morita K, Kimura J, Takeuchi T. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Mod Rheumatol. 2018 Sep 11:1-9. doi: 10.1080/14397595.2018.1500979. [Epub ahead of print]
12. Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018 Aug 3;20(1):165. doi: 10.1186/s13075-018-1673-1.
13. Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, Kuriyama K, Yamazaki H, Morita T, Marui S, Sogabe Y, Kakiuchi N, Matsumori T, Mima A, Nishikawa Y, Ueda T, Tsuda M, Yamauchi Y, Sakuma Y, Maruno T, Uza N, Tsuruyama T, Mimori T, Seno H, Chiba T. Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med. 2018 Aug 8;10(453). pii: eaaq0997. doi: 10.1126/scitranslmed.aaq0997.
14. Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, Uozumi R, Hamaguchi M, Terao C, Yamamoto W, Uda M, Nin K, Morita S, Arai H, Mimori T. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2018 Sep 11:1-7. doi: 10.1080/14397595.2018.1510565. [Epub ahead of print]
15. Yoshiji S, Takahashi K, Sawada K, Mishima M, Eso Y, Morita M, Takai A, Marusawa H, Ueda Y, Mimori T, Seno H. Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis. Intern Med. 2018 Aug 24. doi: 10.2169/internalmedicine.0843-18. [Epub ahead of print]
16. Murakami K, Mimori T. Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Intern Med. 2018 Aug 24. doi: 10.2169/internalmedicine.1423-18. [Epub ahead of print]
17. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, Koike T. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheumatol. 2018 Sep 14:1-23. doi: 10.1080/14397595.2018.1524998. [Epub ahead of print]
18. Miyagawa F, Azukizawa H, Mimori T, Asada H. Anti-PL-12 antibody-positive antisynthetase syndrome with recurrent digital ulcers. J Dermatol. 2018 Sep 19. doi: 10.1111/1346-8138.14661. [Epub ahead of print] No abstract available.
19. Tsuji H, Ikari K, Ohmura K, Yano K, Furu M, Hashimoto M, Ito H, Fujii T, Yamamoto W, Taniguchi A, Yamanaka H, Mimori T, Terao C. Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis. Ann Rheum Dis. 2018 Sep 19. pii: annrheumdis-2018-214022. doi: 10.1136/annrheumdis-2018-214022. [Epub ahead of print] 
20. Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M, Ito H, Fujii T, Tanaka M, Terao C, Kono H, Mori M, Hamaguchi M, Yamamoto W, Ohmura K, Morita S, Mimori T. Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. Scand J Rheumatol. 2018 Sep 30:1-8. doi: 10.1080/03009742.2018.1477989. [Epub ahead of print]
21. Nakagami Y, Sugihara G, Takei N, Fujii T, Hashimoto M, Murakami K, Furu M, Ito H, Uda M, Torii M, Nin K, Murai T, Mimori T. Effect of physical state on pain mediated through emotional health in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23779. [Epub ahead of print]
22. Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, Tanaka M, Fujii T, Omura T, Imai S, Nakagawa T, Yonezawa A, Imai H, Mimori T, Matsubara K. Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. PLoS One. 2018 Nov 2;13(11):e0206943. doi: 10.1371/journal.pone.0206943. eCollection 2018.
23. Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, Yamamoto W, Mimori T, Matsuda S. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2018 Nov 11. doi: 10.1111/1756-185X.13428. [Epub ahead of print]
24. Doi A, Kano S, Asano M, Takahashi Y, Mimori T, Mimori A, Kaneko H. Autoantibodies to killer cell immunoglobulin-like receptor 3DL1 in patients with systemic lupus erythematosus. Clin Exp Immunol. 2018 Nov 13. doi: 10.1111/cei.13235. [Epub ahead of print]
25. Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M, Matsui K, Nakashima R, Hosono Y, Ohmura K, Mimori T, Sano H. Serum neopterin as well as ferritin, soluble interleukin 2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody positive dermatomyositis. Mod Rheumatol. 2018 Nov 19:1-17. doi: 10.1080/14397595.2018.1548918. [Epub ahead of print]
26. Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C, Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M, Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M, Yoshitomi H, Ito H,Ohmura K, R Forrest AR, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani Y, de Hoon M, Yamamoto K, Okada Y. Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Res. 2018 Dec 14;46(22):11898-11909.
27. Miyagawa-Hayashino A,Yoshifuji H, Kitagori K, Ito S, Oku T, Hirayama Y, Salah A, Nakajima T, Kiso K, Yamada N, Haga H, Tsuruyama T.Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes. Arthritis Res Ther. 2018 Jan 30;20(1):13. 
28. Handa T, Matsui S,Yoshifuji H, Kodama Y, Yamamoto H, Minamoto S, Waseda Y, Sato Y, Kubo K, Mimori T, Chiba T, Hirai T, Mishima M.Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Mod Rheumatol. 2018 Sep;28(5):838-844. 
29. Notohara K, Kamisawa T, Uchida K, Zen Y, Kawano M, Kasashima S, Sato Y, Shiokawa M, Uehara T,Yoshifuji H, Hayashi H, Inoue K, Iwasaki K, Kawano H, Matsubayashi H, Moritani Y, Murakawa K, Oka Y, Tateno M, Okazaki K, Chiba T.Gastrointestinal manifestation of immunoglobulin G4-related disease: clarification through a multicenter survey. J Gastroenterol. 2018 Jul;53(7):845-853
30. Nakashima R. Clinical significance of myositis-specific autoantibodies.

    Immunol Med. 2018 Sep;41(3):103-112.

ページトップへ

2017年

1. Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, Koike T. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod Rheumatol. 2017;27:755-765.
2. Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun. 2017;77:116-122.
3. Yaku A, Hashimoto M, Furu M, Ito H, Yamakawa N, Yamamoto W, Fujii T, Matsuda F, Mimori T, Terao C. Relationship between handedness and joint involvement in rheumatoid arthritis. Sci Rep. 2016 Dec 15;6:39180.
4. Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther. 2017;19:9.
5. Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol. 2017;27:217-226.
6. Mori M, Hashimoto M, Matsuo T, Fujii T, Furu M, Ito H, Yoshitomi H, Hirose J, Ito Y, Akizuki S, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Ohmura K, Mimori T. Cell-contact-dependent activation of CD4+ T cells by adhesion molecules on synovial fibroblasts. Mod Rheumatol. 2017;27:448-456.
7. Umehara H, Okazaki K, Nakamura T, Satoh-Nakamura T, Nakajima A, Kawano M, Mimori T, Chiba T. Current approach to the diagnosis of IgG4-related disease – Combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol. 2017;27:381-391.
8. Hiwa R, Ohmura K, Nakabo S, Terao C, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Hashimoto M, Furu M, Ito H, Fujii T, Mimori T. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive. Int J Rheum Dis. 2017;20:731-736.
9. Umehara H, Okazaki K, Kawano M, Mimori T, Chiba T. How to diagnose IgG4-related disease. Ann Rheum Dis. 2017;76:e46.
10. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cerinic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelmann N, Baron M, Atsumi T, Hassoun P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, Allanore Y. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann Rheum Dis. 2017;76:1150-1158.
11. Tsuboi H, Hagiwara S, Asashima H, Takahashi H, Hirota T, Noma H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, Sumida T. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 2017;76:1980-1985.
12. Takeuchi Y, Murakami K, Kuramoto N, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Ohmura K, Mimori T. Clinical Images: Chronic Nonbacterial Osteomyelitis. Arthritis Rheumatol. 2017;69:1660.
13. Nakabo S, Hashimoto M, Ito S, Furu M, Ito H, Fujii T, Yoshifuji H, Imura Y, Nakashima R, Murakami K, Kuramoto N, Tanaka M, Satoh J, Ishigami A, Morita S, Mimori T, Ohmura K. Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Rheumatology (Oxford). 2017;56:1217-1226.
14. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57-64.
15. Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, Kuramoto N, Ito S, Satoh J, Tanaka M, Fujii T, Mimori T, Ohmura K. Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases. J Rheumatol. 2017;44:1384-1388.
16. Hiwa R, Ohmura K, Arase N, Jin H, Hirayasu K, Kohyama M, Suenaga T, Saito F, Terao C, Atsumi T, Iwatani H, Mimori T, Arase H. Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis. Arthritis Rheumatol. 2017;69:2069-2080.
17. Tsuji H, Yano K, Furu M, Yamakawa N, Ikari K, Hashimoto M, Ito H, Fujii T, Yamamoto W, Ohmura K, Taniguchi A, Momohara S, Matsuda F, Allaart CF, Yamanaka H, Mimori T, Terao C. Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. Sci Rep. 2017;7:5856.
18. Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C. Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Sci Rep. 2017;7:6911.
19. Nakajima T, Yoshifuji H, Shimizu M, Kitagori K, Murakami K, Nakashima R, Imura Y, Tanaka M, Ohmura K, Matsuda F, Terao C, Mimori T. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res Ther. 2017;19:197.
20. Okabe N, Ohmura K, Katayama M, Akizuki S, Carpino N, Murakami K, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Tanaka M, Mimori T. Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Mod Rheumatol. 2017 Oct 3:1-11. doi: 10.1080/14397595.2017.1380249. [Epub ahead of print]
21. Terao C, Okada Y, Ikari K, Kochi Y, Suzuki A, Ohmura K, Matsuo K, Taniguchi A, Kubo M, Raychaudhuri S, Yamamoto K, Yamanaka H, Kamatani Y, Mimori T, Matsuda F. Genetic landscape of interactive effects of HLA-DRB1 alleles on susceptibility to ACPA(+) rheumatoid arthritis and ACPA levels in Japanese population. J Med Genet. 2017;54:853-858.
22. Kiso K,Yoshifuji H, Oku T, Hikida M, Kitagori K, Hirayama Y, Nakajima T, Haga H, Tsuruyama T, Miyagawa-Hayashino A.Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients. PLoS One. 2017 Sep 14;12(9):e0184738. 

ページトップへ

2016年

1. Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, Endo K, Mashino N, Yamamoto K: Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus including lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 2016;26:80-6.
2. Iwata T, Ito H, Furu M, Hashimoto M, Fujii T, Ishikawa M, Yamakawa N, Terao C, Azukizawa M, Hamamoto Y, Mimori T, Akiyama H, Matsuda S: Periarticular osteoporosis of the forearm correlated with joint destruction and functional impairment in patients with rheumatoid arthritis. Osteoporos Int. 2016;27:691-701.
3. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, Koike T: Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491-8.
4. Iguchi-Hashimoto M, Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ishikawa M, Ito H, Yamakawa N, Terao C, Yamamoto K, Yamamoto W, Ohmura K, Mimori T: The association between serious infection and disease outcome in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35:213-8.
5. Terao C, Ikari K, Nakayamada S, Takahashi Y, Yamada R, Ohmura K, Hashimoto M, Furu M, Ito H, Fujii T, Yoshida S, Saito K, Taniguchi A, Momohara S, Yamanaka H, Mimori T, Matsuda F: A twin study of rheumatoid arthritis in the Japanese population. Mod Rheumatol. 2016;26:685-9.
6. Damoiseaux J, von Mühlen CA, Garcia-De La Torre I, Carballo OG, de Melo Cruvinel W, Francescantonio PL, Fritzler MJ, Herold M, Mimori T, Satoh M, Andrade LE, Chan EK, Conrad K. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016;7:1.
7. Ishikawa M, Ito H, Furu M, Hashimoto M, Fujii T, Okahata A, Mimori T, Matsuda S. Plasma sLOX-1 is a potent biomarker of clinical remission and disease activity in patients with seropositive RA. Mod Rheumatol. 2016;26:696-701.
8. Fujimoto M, Kaku Y, Yamakawa N, Kawabata D, Ohmura K, Koyanagi I, Mimori T, Kabashima K, Haga H. Methotrexate-associated EBV-positive vasculitis in the skin: a report of two cases simulating rheumatoid vasculitis. J Cutaneous Pathol.  2016; 43:520-525
9. Fujita Y, Fujii T, Shimizu H, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Tanaka M, Masaki Y, Fukushima T, Okazaki T, Umehara H, Mimori T. Isolation of vascular smooth muscle antigen-reactive CD4(+)αβTh1 clones that induce pulmonary vasculitis in MRL/Mp-Fas(+/+) mice. Cell Immunol. 2016;303:50-4
10. Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A, Hashimoto M, Murakami K, Imura Y, Yukawa N, Yoshifuji H, Fujii T, Takaori-Kondo A, Mimori T. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39:64-71.
11. Terao C, Yoshifuji H, Yamano Y, Kojima H, Yurugi K, Miura Y, Maekawa T, Handa H, Ohmura K, Saji H, Mimori T, Matsuda F. Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases. Rheumatology (Oxford). 2016;55:1686-92.
12. Tsuji H, Ohmura K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Fujii T, Mimori T: Efficacy and Safety of grapefruit juice intake combined with tacrolimus treatment against connective tissue disease. Intern Med. 2016;55:1547-52.
13. Okada Y, Suzuki A, Ikari K, Terao C, Kochi Y, Ohmura K, Higasa K, Akiyama M, Ashikawa K, Kanai M, Hirata J, Suita N, Teo YY, Xu H, Bae SC, Takahashi A, Momozawa Y, Matsuda K, Momohara S, Taniguchi A, Yamada R, Mimori T, Kubo M, Brown MA, Raychaudhuri S, Matsuda F, Yamanaka H, Kamatani Y, Yamamoto K. Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. Am J Hum Genet. 2016;99:366-74.
14. Yamakawa N, Oe K, Yukawa N, Murakami K, Nakashima R, Imura Y, Yoshifuji H, Ohmura K, Miura Y, Tomosugi N, Kawabata H, Takaori-Kondo A, Mimori T. A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts. Intern Med. 2016;55:2697-701.
15. Ishikawa Y, Fujii T, Ishikawa SK, Yukawa N, Hashimoto M, Furu M, Ito H, Ohmura K, Mimori T. Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort. PLoS One. 2016;11:e0162896.
16. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takasaki Y, Mimori T, Hiramatsu K, Komatsu S, Tanaka Y. Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatol Ther. 2016;3:129-141.
17. Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H; ABROAD Study Investigators. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. J Rheumatol. 2016;43:1974-1983.
18. Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91-99.
19. van Wesemael TJ, Ajeganova S, Humphreys J, Terao C, Muhammad A, Symmons DP, MacGregor AJ, Hafström I, Trouw LA, van der Helm-van Mil AH, Huizinga TW, Mimori T, Toes RE, Matsuda F, Svensson B, Verstappen SM, van der Woude D. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res Ther. 2016;18(1):285.
20. Yaku A, Hashimoto M, Furu M, Ito H, Yamakawa N, Yamamoto W, Fujii T, Matsuda F, Mimori T, Terao C. Relationship between handedness and joint involvement in rheumatoid arthritis. Sci Rep. 2016 Dec 15;6:39180.
21. Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP, Nakajima T, Ohmura K, Kawabata D, Yukawa N, Imura Y, Murakami K, Nakashima R, Usui T, Fujii T, Sakai K, Yanagita M, Hirayama Y, Mimori T. Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. PLoS One. 2016;11:e0167141.

On Line Publishing

1. Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, Ohmura K, Ishii H, Nakata K, Mimori T. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease.  Mod Rheumatol. 2016 Mar 11:1-6. [Epub ahead of print]

ページトップへ

2015年

1. Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, Naka T: Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud’s phenomenon. Rheumatology (Oxford). 2015;54:349-58.
2. Muro Y, Sugiura K, Mimori T, Akiyama M: DNA mismatch repair enzymes: Genetic defects and autoimmunity. Clin Chim Acta. 2015;442:102-109.
3.  Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T: Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis- Associated Interstitial Lung Disease: A Retrospective Case Control Study. PLoS One. 2015;10:e0120313.
4. Hashimoto M, Yamazaki T, Hamaguchi M, Morimoto T, Yamori M, Asai K, Isobe Y, Furu M, Ito H, Fujii T, Terao C, Mori M, Matsuo T, Yoshitomi H, Yamamoto K, Yamamoto W, Bessho K, Mimori T: Periodontitis and Porphyromonas gingivalis in Preclinical Stage of Arthritis Patients. PLoS One. 2015;10:e0122121.
5.  Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther. 2015;17:57.
6. Katada H, Yukawa N, Urushihara H, Tanaka S, Mimori T, Kawakami K: Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. Clin Rheumatol. 2015;34(5):949-56.
7. Terao C, Asai K, Hashimoto M, Yamazaki T, Ohmura K, Yamaguchi A, Takahashi K, Takei N, Ishii T, Kawaguchi T, Tabara Y, Takahashi M, Nakayama T, Kosugi S, Sekine A, Fujii T, Yamada R, Mimori T, Matsuda F, Bessho K; Nagahama Study Group: Significant association of periodontal disease with anti-citrullinated peptide antibody in a Japanese healthy population – The Nagahama study. J Autoimmun. 2015;59:85-90.
8. Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, Nishina N, Suzuki A, Myouzen K, Kawaguchi T, Takahashi M, Takasugi K, Murasawa A, Mizuki S, Iwahashi M, Funahashi K, Natsumeda M, Furu M, Hashimoto M, Ito H, Fujii T, Ezawa K, Matsubara T, Takeuchi T, Kubo M, Yamada R, Taniguchi A, Yamanaka H, Momohara S, Yamamoto K, Mimori T, Matsuda F: Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares large proportion of susceptibility loci with ACPA-positive RA: -a meta-analysis of genome-wide association study in a Japanese population. Arthritis Res Ther. 2015;17:104.
9. Kiyama K, Yoshifuji H, Kandou T, Hosono Y, Kitagori K, Nakashima R, Imura Y, Yukawa N, Ohmura K, Fujii T, Kawabata D, Mimori T: Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease. BMC Musculoskeletal Dis 2015;16:129.
10. Hirata T, Usui T, Kobayashi S, Mimori T: A novel splice variant of human L-selectin encodes a soluble molecule that is elevated in serum of patients with rheumatic diseases. Biochem Biophys Res Commun. 2015;462:371-7.
11. Nakatsuka Y, Handa T, Nakamoto Y, Nobashi T, Yoshifuji H, Tanizawa K, Ikezoe K, Sokai A, Kubo T, Hirai T, Chin K, Togashi K, Mimori T, Mishima M: Total lesion glycolysis as an IgG4-related disease activity marker. Mod Rheumatol. 2015;25:579-84.
12. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers M, Chari S, Della-Torre E, Frulloni L, Goto H, Hart P, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Löhr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahira M, Takahashi H, Tanaka A, Topazian M, Umehara H, Webster G, Witzig T, Yamamoto M, Zhang W, Chiba T, Stone JH: International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67:1688–1699.
13. Terao C, Yano K, Ikari K, Furu M, Yamakawa N, Yoshida S, Hashimoto M, Ito H, Fujii T, Ohmura K, Yurugi K, Miura Y, Maekawa T, Taniguchi A, Momohara S, Yamanaka H, Mimori T, Matsuda F: Brief Report: Main Contribution of DRB1*04:05 Among the Shared Epitope Alleles and Involvement of DRB1 Amino Acid Position 57 in Association With Joint Destruction in Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis. Arthritis Rheumatol. 2015;67:1744-50.
14. Terao C, Suzuki A, Ikari K, Kochi Y, Ohmura K, Katayama M, Nakabo S, Yamamoto N, Suzuki T, Iwamoto T, Yurugi K, Miura Y, Maekawa T, Takasugi K, Kubo M, Saji H, Taniguchi A, Momohara S, Yamamoto K, Yamanaka H, Mimori T, Matsuda F: An association between the 74th amino acid position of HLA-DRB1 and ACPA levels of Japanese ACPA-positive RA. Arthritis Rheumatol. 2015;67:2038-45.
15. Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, Nishina N, Suzuki A, Myouzen K, Kawaguchi T, Takahashi M, Takasugi K, Murasawa A, Mizuki S, Iwahashi M, Funahashi K, Natsumeda M, Furu M, Hashimoto M, Ito H, Fujii T, Ezawa K, Matsubara T, Takeuchi T, Kubo M, Yamada R, Taniguchi A, Yamanaka H, Momohara S, Yamamoto K, Mimori T, Matsuda F: Takayasu arteritis and ulcerative colitis –high concurrence ratio and genetic overlap. Arthritis Rheumatol. 2015;67:2226-32.
16. Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LEC: Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) 2014-2015. Front Immunol 2015;6: 412, 2015.
17. Hamamoto Y, Ito H, Furu M, Hashimoto M, Fujii T, Ishikawa M, Yamakawa N, Terao C, Azukizawa M, Iwata T, Mimori T, Matsuda S: Serological and Progression Differences of Joint Destruction in the Wrist and the Feet in Rheumatoid Arthritis – A Cross-Sectional Cohort Study. PLoS One. 2015;10:e0136611.
18. Honda Y, Tanizaki H, Otsuka A, Shirakashi M, Imura Y, Mimori T, Miyachi Y, Kabashima K: Disseminated Mycobacterium mantenii Infection with Multiple Purulent Cutaneous Lesions. Acta Derm Venereol. 2015;95:1028-1029.
19. Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Yoshida S, Furu M, Hashimoto M, Ito H, Fujii T, Ohmura K, Murakami K, Takahashi M, Hamaguchi M, Tabara Y, Taniguchi A, Momohara S, Raychaudhuri S, Allaart CF, Yamanaka H, Mimori T, Matsuda F: Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:3113-23.
20. Kono M, Miura N, Fujii T, Ohmura K, Yoshifuji H, Yukawa N, Imura Y, Nakashima R, Ikeda T, Umemura S, Miyatake T, Mimori T: Personal Authentication Analysis Using Finger-Vein Patterns in Patients with Connective Tissue Diseases-Possible Association with Vascular Disease and Seasonal Change. PLoS One. 2015;10:e0144952.
21. Honda Y, Tanizaki H, Otsuka A, Shirakashi M, Imura Y, Mimori T, Miyachi Y, Kabashima K: Disseminated Mycobacterium mantenii Infection with Multiple Purulent Cutaneous Lesions. Acta Derm Venereol. 2015;95:1028-1029.

On Line Publishing

1. Hamada M, Tanaka I, Sakurai Y, Hosono Y, Mimori T: Juvenile polymyositis associated with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody in a 13-year-old girl. Mod Rheumatol. 2015 Feb 20. [Published online]
2. Terao C, Yoshifuji H, Nakajima T, Yukawa N, Matsuda F, Mimori T: Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol. 2015 Aug 27:1-3. [Published online]

ページトップへ

2014年

1. Washio M, Fujii T, Kuwana M, Kawaguchi Y, Mimori A, Horiuchi T, Tada Y, Takahashi H, Mimori T; Japan MCTD study group. Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus. Mod Rheumatol. 24(5):788-92, 2014.
2. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium; GARNET consortium, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 506(7488):376-81. 2014.
3. Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Rheumatol Int. 34(12):1729-36, 2014.
4. Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; RESEARCH investigators; REAL Study Group. Mod Rheumatol. 24(4):572-9, 2014.
5. Terao C, Ohmura K, Yamada R, Kawaguchi T, Shimizu M, Tabara Y, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Matsuda F, Mimori T; Nagahama Study Group. Association between antinuclear antibodies and the HLA class II locus and heterogeneous characteristics of staining patterns: the Nagahama study. Arthritis Rheumatol. 66(12):3395-403, 2014.
6. Muro Y, Nakashima R, Hosono Y, Sugiura K, Mimori T, Akiyama M. Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis. Arthritis Rheumatol. 66(12):3457-62, 2014.
7. Terao C, Ohmura K, Ikari K, Kawaguchi T, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Tabara Y, Taniguchi A, Momohara S, Yamanaka H, Yamada R, Matsuda F, Mimori T; Nagahama Study Group. Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population. Arthritis Care Res (Hoboken). 66(12):1818-27, 2014.
8. Ishikawa Y, Usui T, Shiomi A, Shimizu M, Murakami K, Mimori T. Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice. Eur J Immunol. 44(11):3453-63, 2014.
9. Kato M, Oiso N, Nozaki Y, Inoue A, Hosono Y, Funauchi M, Mimori T, Matsumura I, Kawada A. Antitumor necrosis factor alpha inhibitor-induced dermatomyositis and interstitial lung disease with anti-PL12 autoantibody: signs of antisynthetase syndrome. J Dermatol. 41(11):1034-6, 2014.
10. Ito Y, Hashimoto M, Hirota K, Ohkura N, Morikawa H, Nishikawa H, Tanaka A, Furu M, Ito H, Fujii T, Nomura T, Yamazaki S, Morita A, Vignali DA, Kappler JW, Matsuda S, Mimori T, Sakaguchi N, Sakaguchi S. Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science. 346(6207):363-8, 2014.
11. Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J Immunol. 193(2):849-59, 2014.
12. Ozaki T, Yamashita H, Hosono Y, Nakashima R, Mimori T, Takahashi Y, Kaneko H, Kano T, Mimori A. Two patients in the same family with anti-ARS antibody-associated myositis. Mod Rheumatol. 24(4):699-700, 2014.
13. Terao C, Yoshifuji H, Mimori T. Recent advances in Takayasu arteritis. Int J Rheum Dis. 17(3):238-47, 2014.
14. Tanaka K, Terao C, Ohmura K, Takahashi M, Nakashima R, Imura Y, Yoshifuji H, Yukawa N, Usui T, Fujii T, Mimori T, Matsuda F. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. J Hum Genet. 59(2):107-9, 2014.
15. Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Ohmura K, Fujii T, Kitano T, Kondo T, Yurugi K, Miura Y, Maekawa T, Saji H, Takaori-Kondo A, Matsuda F, Haga H, Mimori T. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 41(2):293-9, 2014.
16. Nakajima T, Kawabata D, Nakabo S, Miyagawa-Hayashino A, Yukawa N, Yoshifuji H, Ohmura K, Fujii T, Mimori T. Successful treatment with tocilizumab in a case of intralymphatic histiocytosis associated with rheumatoid arthritis. Intern Med. 53(19):2255-8, 2014.

On Line Publishing

1. Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, Yamamoto K, Yamamoto W, Matsuo T, Mori M, Ohmura K, Kawabata H, Mimori T. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PLoS One. 9(5):e98202,  2014.
2. Terao C, Hashimoto M, Furu M, Nakabo S, Ohmura K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Matsuda F, Ito H, Fujii T, Mimori T. Inverse association between air pressure and rheumatoid arthritis synovitis. PLoS One. 9(1):e85376, 2014.
3. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 9(1):e85062, 2014.
4. Tsuji H, Yoshifuji H, Fujii T, Matsuo T, Nakashima R, Imura Y, Yukawa N, Ohmura K, Sumiyoshi S, Mimori T: Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis. Mod Rheumatol. 2014 Aug 27. [Epub ahead of print]

ページトップへ

2013年

1. Low Prevalence of Anti-DFS70/LEDGF Antibodies in Patients with Dermatomyositis and Other Systemic Autoimmune Rheumatic Diseases. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. J Rheumatol. 2013 Jan;40(1):92-3.
2. Neutrophils are essential as a source of IL-17 in the effector phase of arthritis. Katayama M, Ohmura K, Yukawa N, Terao C, Hashimoto M, Yoshifuji H, Kawabata D, Fujii T, Iwakura Y, Mimori T. PLoS One. 2013 May 6;8(5):e62231.
3. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedr?n S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. PLoS Genet. 2013 Mar;9(3):e1003394.
4. Three groups in the 28 joints for rheumatoid arthritis synovitis–analysis using more than 17,000 assessments in the KURAMA database. Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T. PLoS One. 2013;8(3):e59341.
5. Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis. Ishigaki K, Maruyama J, Hagino N, Murota A, Takizawa Y, Nakashima R, Mimori T, Setoguchi K. Rheumatol Int. 2013 Apr 4.
6. The prognostic value of HRCT in myositis-associated interstitial lung disease. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, Ikezoe K, Watanabe K, Taguchi Y, Hatta K, Oga T, Chin K, Nagai S, Mimori T, Mishima M. Respir Med. 2013 May;107(5):745-52.
7. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. J Rheumatol. 2013 Jan;40(1):92-3.
8. Validation of different sets of criteria for the diagnosis of Sj?gren’s syndrome in Japanese patients. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, Sumida T. Mod Rheumatol. 2013 Mar;23(2):219-25.
9. Clinical Features and Treatment of Multicentric Castleman’s Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A. J Clin Exp Hematop. 2013;53(1):69-77.
10. Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Plenge RM, Greenberg JD, Mangravite LM, Derry JM, Stahl EA, Coenen MJ, Barton A, Padyukov L, Klareskog L, Gregersen PK, Mariette X, Moreland LW, Bridges SL Jr, de Vries N, Huizinga TW, Guchelaar HJ; International Rheumatoid Arthritis Consortium (INTERACT), Friend SH, Stolovitzky G. Nat Genet. 2013 May;45(5):468-9.
11. Two Susceptibility Loci to Takayasu Arteritis Reveal a Synergistic Role of the IL12B and HLA-B Regions in a Japanese Population. Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, Shimizu M, Kawaguchi T, Chen Z, Naruse TK, Sato-Otsubo A, Ebana Y, Maejima Y, Kinoshita H, Murakami K, Kawabata D, Wada Y, Narita I, Tazaki J, Kawaguchi Y, Yamanaka H, Yurugi K, Miura Y, Maekawa T, Ogawa S, Komuro I, Nagai R, Yamada R, Tabara Y, Isobe M, Mimori T, Matsuda F. Am J Hum Genet. 2013 Jul 2.
12. Comprehensive microRNA Analysis Identifies miR-24 and miR-125a-5p as Plasma Biomarkers for Rheumatoid Arthritis. Murata K, Furu M, Yoshitomi H, Ishikawa M, Shibuya H, Hashimoto M, Imura Y, Fujii T, Ito H, Mimori T, Matsuda S. PLoS One. 2013 Jul 18;8(7):e69118.
13. Association of Takayasu arteritis with HLA-B*67:01 and two amino acids in HLA-B protein. Terao C, Yoshifuji H, Ohmura K, Murakami K, Kawabata D, Yurugi K, Tazaki J, Kinoshita H, Kimura A, Akizuki M, Kawaguchi Y, Yamanaka H, Miura Y, Maekawa T, Saji H, Mimori T, Matsuda F. Rheumatology (Oxford). 2013 Jul 19.

ページトップへ

2012年

1. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H. Mod Rheumatol. 2012 Jan 5. [Epub ahead of print]
2. Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01. Terao C, Ikari K, Ohmura K, Suzuki T, Iwamoto T, Takasugi K, Saji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T. Ann Rheum Dis. 2012 Jan 10. [Epub ahead of print]
3. Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Umehara H, Mimori T. FEBS Lett. 2012 Jan 17. [Epub ahead of print]
4. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, Yoshifuji H, Kawabata D, Ohmura K, Usui T, Fujii T, Mimori T. Mod Rheumatol. 2012 Jan 24. [Epub ahead of print]
5. A Genome-Wide Association Study Identified AFF1 as a Susceptibility Locus for Systemic Lupus Eyrthematosus in Japanese. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K, Kamachi M, Kawaguchi Y, Ikari K, Mohammed OW, Matsuda K, Terao C, Ohmura K, Myouzen K, Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Yamanaka H, Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakamura Y, Yamamoto K. PLoS Genet. 2012 Jan;8(1):e1002455. Epub 2012 Jan 26.
6. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Kawaguchi T, Stahl EA, Kurreeman FA, Nishida N, Ohmiya H, Myouzen K, Takahashi M, Sawada T, Nishioka Y, Yukioka M, Matsubara T, Wakitani S, Teshima R, Tohma S, Takasugi K, Shimada K, Murasawa A, Honjo S, Matsuo K, Tanaka H, Tajima K, Suzuki T, Iwamoto T, Kawamura Y, Tanii H, Okazaki Y, Sasaki T, Gregersen PK, Padyukov L, Worthington J, Siminovitch KA, Lathrop M, Taniguchi A, Takahashi A, Tokunaga K, Kubo M, Nakamura Y, Kamatani N, Mimori T, Plenge RM, Yamanaka H, Momohara S, Yamada R, Matsuda F, Yamamoto K. Nat Genet. 2012 Mar 25. doi: 10.1038/ng.2231. [Epub ahead of print]
7. Time-dependent increased risk for serious infection from continuous use of TNF antagonists during three years in rheumatoid arthritis patients. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; for the REAL Study Group. Arthritis Care Res (Hoboken). 2012 Mar 15. doi: 10.1002/acr.21666. [Epub ahead of print]
8. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. Harigai M, Tanaka Y, Maisawa S; JA21963 Study Group. J Rheumatol. 2012 Mar;39(3):486-95. Epub 2012 Jan 15.
9. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; for the REAL Study Group. Ann Rheum Dis. 2012 Apr 13. [Epub ahead of print]
10. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Kiyama K, Kawabata D, Hosono Y, Kitagori K, Yukawa N, Yoshifuji H, Omura K, Fujii T, Mimori T. Arthritis Res Ther. 2012 Apr 24;14(2):R86. [Epub ahead of print]
11. ACPA-Negative RA Consists of Two Genetically Distinct Subsets Based on RF Positivity in Japanese. Terao C, Ohmura K, Ikari K, Kochi Y, Maruya E, Katayama M, Yurugi K, Shimada K, Murasawa A, Honjo S, Takasugi K, Matsuo K, Tajima K, Suzuki A, Yamamoto K, Momohara S, Yamanaka H, Yamada R, Saji H, Matsuda F, Mimori T. PLoS One. 2012;7(7):e40067. Epub 2012 Jul 6.
12. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M; Iguratimod-Clinical Study Group. Mod Rheumatol. 2012 Jul 26. [Epub ahead of print]
13. Functional Variants in NFKBIE and RTKN2 Involved in Activation of the NF-κB Pathway Are Associated with Rheumatoid Arthritis in Japanese. Myouzen K, Kochi Y, Okada Y, Terao C, Suzuki A, Ikari K, Tsunoda T, Takahashi A, Kubo M, Taniguchi A, Matsuda F, Ohmura K, Momohara S, Mimori T, Yamanaka H, Kamatani N, Yamada R, Nakamura Y, Yamamoto K. PLoS Genet. 2012 Sep;8(9):e1002949.
14. Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells. Nakano M, Fujii T, Hashimoto M, Yukawa N, Yoshifuji H, Ohmura K, Nakaizumi A, Mimori T. Clin Exp Immunol. 2012 Oct;170(1):94-100.
15. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, Mimori T. Arthritis Rheum. 2013 Feb;65(2):472-80.
16. Validation of different sets of criteria for the diagnosis of Sj?gren’s syndrome in Japanese patients. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, Sumida T. Mod Rheumatol. 2012 Dec 28.
17. Identification of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel target of bisphenol A. Ito Y, Ito T, Karasawa S, Enomoto T, Nashimoto A, Hase Y, Sakamoto S, Mimori T, Matsumoto Y, Yamaguchi Y, Handa H. PLoS One. 2012;7(12):e50481.
18. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Kunimasa K, Arita M, Nakazawa T, Tanaka M, Tsubouchi K, Konishi S, Fukuda Y, Saigusa M, Nakagawa H, Ubukata S, Korogi Y, Fujii T, Mimori T, Ishida T. Intern Med. 2012;51(24):3405-10.

ページトップへ

2011年

1. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Van Praet JT, Van Steendam K, Smith V, De Bruyne G, Mimori T, Bonroy C, Elewaut D, Deforce D, De Keyser F. Rheumatology (Oxford). 2011 Feb 17.
2. Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M. J Rheumatol. 2011 Apr 15. [Epub ahead of print]
3. The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y; Human Disease Genomics Working Group; RA Clinical and Genetic Study Consortium, Okada Y, Nakamura Y, Yamamoto K, Melchers I, Lathrop M, Mimori T, Matsuda F. Hum Mol Genet. 2011 Apr 19.
4. Antigen Is Required for Maturation and Activation of Pathogenic Anti-DNA Antibodies and Systemic Inflammation. Venkatesh J, Yoshifuji H, Kawabata D, Chinnasamy P, Stanevsky A, Grimaldi CM, Cohen-Solal J, Diamond B. J Immunol. 2011 May 1;186(9):5304-12. Epub 2011 Mar 28.
5. Interferon-{gamma} release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Takeda N, Nojima T, Terao C, Yukawa N, Kawabata D, Ohmura K, Usui T, Fujii T, Ito Y, Iinuma Y, Mimori T. Lupus. 2011 May 11. [Epub ahead of print]
6. A trans-ethnic genetic study of rheumatoid arthritis identified FCGR2A as a candidate common risk factor in Japanese and European populations. Meziani R, Yamada R, Takahashi M, Ohigashi K, Morinobu A, Terao C, Hiratani H, Ohmura K, Yamaguchi M, Nomura T, Vasilescu A, Kokubo M, Renault V, Hirosawa K, Ratanajaraya C, Heath S, Mimori T, Sakaguchi S, Lathrop M, Melchers I, Kumagai S, Matsuda F. Mod Rheumatol. 2011 May 24. [Epub ahead of print]
7. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Oga T, Chin K, Nagai S, Mimori T, Mishima M. Respir Med. 2011 May 31. [Epub ahead of print]
8. Myelin basic protein as a novel genetic risk factor in rheumatoid arthritis-a genome-wide study combined with immunological analyses. Terao C, Ohmura K, Katayama M, Takahashi M, Kokubo M, Diop G, Toda Y, Yamamoto N; Human Disease Genomics Working Group; Rheumatoid Arthritis (RA) Clinical and Genetic Study Consortium, Shinkura R, Shimizu M, Gut I, Heath S, Melchers I, Manabe T, Lathrop M, Mimori T, Yamada R, Matsuda F. PLoS One. 2011;6(6):e20457. Epub 2011 Jun 3.
9. Polymyositis associated with autoimmune hepatitis, primary biliary cirrhosis, and autoimmune thrombocytopenic purpura. Kurihara Y, Shishido T, Oku K, Takamatsu M, Ishiguro H, Suzuki A, Sekita T, Shinagawa T, Ishihara T, Nakashima R, Fujii T, Okano Y. Mod Rheumatol. 2011 Jun;21(3):325-9. Epub 2011 Jan 15.
10. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, Kobashi Y, Kubo T, Aihara K, Chin K, Nagai S, Mimori T, Mishima M. Respir Med. 2011 Aug;105(8):1238-47. Epub 2011 Apr 22.
11. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nakajima A, Atsumi T, Yasuda S, Tanaka Y, Saito K, Tohma S, Fujii T, Ihata A, Tamura N, Kawakami A, Sugihara T, Ito S, Miyasaka N, Harigai M. Mod Rheumatol. 2011 Aug;21(4):444-8. Epub 2011 Feb 11.
12. Developing an electronic health record for intractable diseases in Japan. Kimura E, Kobayashi S, Kanatani Y, Ishihara K, Mimori T, Takahashi R, Chiba T, Yoshihara H. Stud Health Technol Inform. 2011;169:255-9.
13. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D; The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. Mod Rheumatol. 2011 Sep 1. [Epub ahead of print]
14. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, Ichinose K, Nakamura H, Tsujino A, Kawakami A, Matsunaka M, Kasagi S, Kawano S, Kumagai S, Ohmura K, Mimori T, Hirano M, Ueno S, Tanaka K, Tanaka M, Toyoshima I, Sugino H, Yamakawa A, Tanaka K, Niikawa N, Furukawa F, Murata S, Eguchi K, Ida H, Yoshiura K. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14914-9. Epub 2011 Aug 18.
15. A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, Shimada K, Murasawa A, Honjo S, Takasugi K, Matsuo K, Tajima K, Suzuki A, Yamamoto K, Momohara S, Yamanaka H, Yamada R, Saji H, Matsuda F, Mimori T. Ann Rheum Dis. 2011 Aug 27. [Epub ahead of print]
16. Serum IgG levels demonstrate seasonal change in connective tissue diseases: a large-scale, 4-year analysis in Japanese. Terao C, Ohmura K, Yamamoto K, Yukawa N, Kawabata D, Nojima T, Fujii T, Mimori T. Mod Rheumatol. 2011 Oct 9. [Epub ahead of print]
17. Overexpression of a Minimal Domain of Calpastatin Suppresses IL-6 Production and Th17 Development via Reduced NF-κB and Increased STAT5 Signals. Iguchi-Hashimoto M, Usui T, Yoshifuji H, Shimizu M, Kobayashi S, Ito Y, Murakami K, Shiomi A, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T. PLoS One. 2011;6(10):e27020. Epub 2011 Oct 27.
18. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K. Mod Rheumatol. 2011 Dec 9. [Epub ahead of print]
19. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T, Ohmura K, Usui T, Mimori T. Arthritis Res Ther. 2011 Dec 22;13(6):R213. [Epub ahead of print]
20. Prevention of fasting-mediated bone marrow atrophy by leptin administration. Fujita Y, Yanagida H, Mimori T, Jin ZX, Sakai T, Kawanami T, Sawaki T, Masaki Y, Fukushima T, Okazaki T, Umehara H. Cell Immunol. 2011 Dec 4. [Epub ahead of print]
21. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Chen F, Wang D, Shu X, Nakashima R, Wang G. Rheumatol Int. 2011 Dec 25. [Epub ahead of print]

ページトップへ

2010年

1. Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. Kawabata D, Venkatesh J, Ramanujam M, Davidson A, Grimaldi CM, Diamond B. PLoS One. 2010 Jan 6;5(1):e8418.
2. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, Kawabata D, Ohmura K, Usui T, Fujii T, Okawa K, Mimori T. Rheumatology (Oxford). 2010 Mar;49(3):433-40. Epub 2009 Dec 16.
3. Opinions of Japanese rheumatology physicians regarding clinical practice guidelines. Higashi T, Nakayama T, Fukuhara S, Yamanaka H, Mimori T, Ryu J, Yonenobu K, Murata N, Matsuno H, Ishikawa H, Ochi T. Int J Qual Health Care. 2010 Apr;22(2):78-85. Epub 2010 Jan 15.
4. Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, Oshima H, Kawai S, Hama N, Yamada H, Mimori T, Amano K, Tanaka Y, Matsuoka Y, Yamamoto S, Matsubara T, Murata N, Asai T, Suzuki Y; Study Group for the Japanese Ministry of Health, Labor and Welfare, Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis Program. J Rheumatol. 2010 Apr;37(4):723-9. Epub 2010 Mar 1.
5. Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human systemic lupus erythematosus. Yamaguchi H, Fujimoto T, Nakamura S, Ohmura K, Mimori T, Matsuda F, Nagata S. Eur J Immunol. 2010 Jun;40(6):1778-85.
6. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, Yamazaki K, Hosono N, Myouzen K, Tsunoda T, Kamatani N, Furuichi T, Ikegawa S, Ohmura K, Mimori T, Matsuda F, Iwamoto T, Momohara S, Yamanaka H, Yamada R, Kubo M, Nakamura Y, Yamamoto K. Nat Genet. 2010 Jun;42(6):515-9. Epub 2010 May 9.
7. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, Prieto-Martin P, Nomura T, Sakaguchi N, K?hl J, Heyman B, Takahashi M, Fujita T, Mimori T, Sakaguchi S. J Exp Med. 2010 Jun 7;207(6):1135-43. Epub 2010 May 10.
8. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T; RRR study investigators. Ann Rheum Dis. 2010 Jul;69(7):1286-91. Epub 2010 Apr 1.
9. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Rheumatology (Oxford). 2010 Sep;49(9):1726-33. Epub 2010 May 25.
10. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Sato T, Fujii T, Yokoyama T, Fujita Y, Imura Y, Yukawa N, Kawabata D, Nojima T, Ohmura K, Usui T, Mimori T. Arthritis Rheum. 2010 Dec;62(12):3730-40. doi: 10.1002/art.27700.
11. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, Murasawa A, Honjo S, Takasugi K, Tohma S, Matsuo K, Tajima K, Yukawa N, Kawabata D, Nojima T, Fujii T, Yamada R, Saji H, Matsuda F, Mimori T. Rheumatology (Oxford). 2010 Dec;49(12):2298-304. Epub 2010 Sep 9.
12. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1–analysis of their binding with TGF-β superfamily proteins. Tanaka M, Murakami K, Ozaki S, Imura Y, Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, Usui T, Masaki Y, Fukushima T, Jin ZX, Umehara H, Mimori T. FEBS J. 2010 Oct;277(20):4278-89. doi: 10.1111/j.1742-4658.2010.07816.x. Epub 2010 Sep 22.
13. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, Song YW. BMC Musculoskelet Disord. 2010 Sep 28;11:223.
14. Clinical findings in parvovirus B19 infection in 30 adult patients in Kyoto. Oiwa H, Shimada T, Hashimoto M, Kawaguchi A, Ueda T, Sugiyama E, Kamiya T. Mod Rheumatol. 2011 Feb;21(1):24-31. Epub 2010 Aug 4.

ページトップへ

2009年

1. Selective regulation of autoreactive B cells by FcgammaRIIB. Venkatesh J, Kawabata D, Kim S, Xu X, Chinnasamy P, Paul E, Diamond B, Grimaldi CM. J Autoimmun. 2009 May-Jun;32(3-4):149-57. Epub 2009 Mar 26.
2. Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in a Japanese population. Kyogoku C, Morinobu A, Nishimura K, Sugiyama D, Hashimoto H, Tokano Y, Mimori T, Terao C, Matsuda F, Kuno T, Kumagai S. Mod Rheumatol. 2009;19(4):401-6. Epub 2009 May 8.
3. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice. Fujii T, Okada M, Fujita Y, Sato T, Tanaka M, Usui T, Umehara H, Mimori T. J Autoimmun. 2009 Sep;33(2):125-34. Epub 2009 Jul 12.
4. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, Nakamura T, Shimizu M, Kawabata D, Yukawa N, Hashimoto M, Sakaguchi N, Sakaguchi S, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Mimori T. Arthritis Rheum. 2009 Aug;60(8):2294-303.
5. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M. Rheumatology (Oxford). 2009 Dec;48(12):1570-4. Epub 2009 Oct 5.
6. Kitaori T, Ito H, Yoshitomi H, Aoyama T, Fujii T, Mimori T, Nakamura T. Severe erosive arthropathy requiring surgical treatments in systemic lupus erythematosus. Mod Rheumatol. 19(4):431-6, 2009.
7. Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med. 48(15):1307-9, 2009.
8. Kondo T, Inoue H, Usui T, Mimori T, Tomimoto H, Vernino S, Takahashi R. Autoimmune autonomic ganglionopathy with Sjögren’s syndrome: significance of ganglionic acetylcholine receptor antibody and therapeutic approach. Auton Neurosci. 146(1-2):33-5, 2009.

ページトップへ

2008年

1. Jin ZX, Huang CR, Dong L, Goda S, Kawanami T, Sawaki T, Sakai T, Tong XP, Masaki Y, Fukushima T, Tanaka M, Mimori T, Tojo H, Bloom ET, Okazaki T, Umehara H. Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int Immunol. 20(11):1427-37, 2008.
2. Fujita Y, Fujii T, Nakashima R, Tanaka M, Mimori T. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol. 18(2):184-8, 2008.

ページトップへ

2007年

1. Efficacy and safety of mizoribine for the treatment of Sj?gren’s syndrome: a multicenter open-label clinical trial. Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, Minota S, Nara H, Kondo H, Okada J, Mimori T, Yoshifuji H, Sano H, Hashimoto N, Sugai S, Tanaka Y. Mod Rheumatol. 2007;17(6):464-9. Epub 2007 Dec 20.
2. Incidence of pulmonary hypertension and its clinical relevance in patients with interstitial pneumonias: comparison between idiopathic and collagen vascular disease associated interstitial pneumonias. Handa T, Nagai S, Miki S, Ueda S, Yukawa N, Fushimi Y, Ito Y, Ohta K, Mimori T, Mishima M, Izumi T. Intern Med. 2007;46(12):831-7. Epub 2007 Jun 15.
3. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, Song YW, Mimori T, Targoff IN. Arthritis Rheum. 2007 Apr;56(4):1295-303.
4. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y. Ann Rheum Dis. 2007 Apr;66(4):470-5. Epub 2006 Nov 15.

ページトップへ

2006年

1. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, Mimori T. Autoimmunity. 2006 May;39(3):233-41.

ページトップへ

2005年

1. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, Oshima H, Kawai S, Hama N, Yamada H, Mimori T, Amano K, Tanaka Y, Matsuoka Y, Yamamoto S, Matsubara T, Murata N, Asai T, Suzuki Y; MTX-BUC Combination Study Group; Japanese Ministry of Health; Labour and Welfare’s “Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis”. Mod Rheumatol. 2005;15(5):323-8.

ページトップへ